Ignite Creation Date:
2025-12-24 @ 12:43 PM
Ignite Modification Date:
2026-04-22 @ 7:54 AM
Study NCT ID:
NCT03210961
Status:
COMPLETED
Last Update Posted:
2020-03-31
First Post:
2017-07-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C000720458', 'term': 'ropsacitinib'}, {'id': 'D013535', 'term': 'Suspensions'}], 'ancestors': [{'id': 'D003102', 'term': 'Colloids'}, {'id': 'D045424', 'term': 'Complex Mixtures'}, {'id': 'D004304', 'term': 'Dosage Forms'}, {'id': 'D004364', 'term': 'Pharmaceutical Preparations'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrials.gov_Inquiries@pfizer.com', 'phone': '1-800-718-1021', 'title': 'Pfizer ClinicalTrials.gov Call Center', 'organization': 'Pfizer, Inc.'}, 'certainAgreement': {'otherDetails': 'Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'Baseline up to Day 8 for SAD Cohorts, which included PF-06826647 3mg, 10mg, 30mg, 100mg, 400mg, and 1600mg SD cohorts as well as placebo matching each SAD cohort. Baseline up to Day 28 for MAD Cohorts, which included PF-06826647 30mg, 100mg, 400mg, 1200mg QD, 200mg BID, 400mg QD JP, as well as placebo matching each MAD cohort. Baseline up to Day 84 for Psoriasis Cohorts, which included PF-06826647 400mg and 100mg QD cohorts, as well as placebo matching each psoriasis cohort.', 'description': 'The requirements for recording safety events on the CRF and for reporting safety events on the Clinical Trial Serious Adverse Event Report Form to Pfizer Safety were delineated for 3 types of events: (1) SAEs; (2) non-serious adverse events (AEs); and (3) exposure to the investigational product under study during pregnancy or breastfeeding, and occupational exposure.', 'eventGroups': [{'id': 'EG000', 'title': 'Placebo SAD', 'description': 'During the SAD period (Period 1), the healthy participants received placebo matching PF-06826647 3, 10, 30, 100, 400, or 1600 mg cohort SD cohort in fasted state. SAD period duration was 8 days. (Those placebo participants matching 30, 100, 400, or 1600 SD cohort later continued into MAD period and received the placebo matching 30, 100, 400, or 1200 mg QD cohort, respectively.)', 'otherNumAtRisk': 13, 'deathsNumAtRisk': 13, 'otherNumAffected': 1, 'seriousNumAtRisk': 13, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Placebo QD MAD (JP Placebo Included)', 'description': 'This arm includes both non-Japanese and Japanese participants. In MAD period (Period 2), the non-Japanese participants (they had completed the SAD period) received placebo matching PF-06826647 30, 100, 400, or 1200 mg QD cohort while the Japanese participants (they did not take part in SAD period) received placebo matching PF-06826647 400 mg QD Japanese cohort, both for 10 days with standard meal. MAD period duration was 28 days.', 'otherNumAtRisk': 9, 'deathsNumAtRisk': 9, 'otherNumAffected': 2, 'seriousNumAtRisk': 9, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Placebo BID', 'description': 'Edit During the MAD period (Period 2), the healthy participants received placebo matching PF-06826647 200 mg BID cohort for 10 days with standard meal. MAD period duration was 28 days.', 'otherNumAtRisk': 2, 'deathsNumAtRisk': 2, 'otherNumAffected': 0, 'seriousNumAtRisk': 2, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'PF-06826647 3 mg SAD', 'description': 'During the SAD period (Period 1), the healthy participants received PF-06826647 3 mg SD in fasted state. SAD period duration was 8 days.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 0, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'PF-06826647 10 mg SAD', 'description': 'During the SAD period (Period 1), the healthy participants received PF-06826647 10 mg SD in fasted state. SAD period duration was 8 days.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 0, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG005', 'title': 'PF-06826647 30 mg SAD', 'description': 'During the SAD period (Period 1), the healthy participants received PF-06826647 30 mg SD in fasted state. SAD period duration was 8 days. (These participants later continued into PF-06826647 30 mg QD in MAD period.)', 'otherNumAtRisk': 8, 'deathsNumAtRisk': 8, 'otherNumAffected': 0, 'seriousNumAtRisk': 8, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG006', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'During the MAD period (Period 2), the healthy participants who had taken PF-06826647 30 mg SD received PF-06826647 30 mg QD for 10 days with standard meal. MAD period duration was 28 days.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 2, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG007', 'title': 'PF-06826647 100 mg SAD', 'description': 'During the SAD period (Period 1), the healthy participants received PF-06826647 100 mg SD in fasted state. SAD period duration was 8 days. (These participants later continued into PF-06826647 100 mg QD in MAD period.)', 'otherNumAtRisk': 7, 'deathsNumAtRisk': 7, 'otherNumAffected': 1, 'seriousNumAtRisk': 7, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG008', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'During the MAD period (Period 2), the healthy participants who had taken PF-06826647 100 mg SD received PF-06826647 100 mg QD for 10 days with standard meal. MAD period duration was 28 days.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 1, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG009', 'title': 'PF-06826647 400 mg SAD', 'description': 'During the SAD period (Period 1), the healthy participants received PF-06826647 400 mg SD in fasted state. SAD period duration was 8 days. (These participants later continued into PF-06826647 400 mg QD in MAD period.)', 'otherNumAtRisk': 8, 'deathsNumAtRisk': 8, 'otherNumAffected': 0, 'seriousNumAtRisk': 8, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG010', 'title': 'PF-06826647 400 mg QD MAD', 'description': 'During the MAD period (Period 2), the healthy participants who had taken PF-06826647 400 mg SD received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 1, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG011', 'title': 'PF-06826647 1600 mg SAD', 'description': 'During the SAD period (Period 1), the healthy participants received PF-06826647 1600 mg SD in fasted state. SAD period duration was 8 days. (These participants later continued into PF-06826647 1200 mg QD in MAD period.)', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 2, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG012', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'During the MAD period (Period 2), the healthy participants who had taken PF-06826647 1600 mg SD received PF-06826647 1200 mg QD for 10 days with standard meal. MAD period duration was 28 days.', 'otherNumAtRisk': 5, 'deathsNumAtRisk': 5, 'otherNumAffected': 1, 'seriousNumAtRisk': 5, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG013', 'title': 'PF-06826647 200 mg BID', 'description': 'During the MAD period (Period 2), the healthy participants received PF-06826647 200 mg BID for 10 days with standard meal. MAD period duration was 28 days.', 'otherNumAtRisk': 7, 'deathsNumAtRisk': 7, 'otherNumAffected': 3, 'seriousNumAtRisk': 7, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG014', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), the Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.', 'otherNumAtRisk': 5, 'deathsNumAtRisk': 5, 'otherNumAffected': 1, 'seriousNumAtRisk': 5, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG015', 'title': 'Placebo QD PSO', 'description': 'In the psoriasis (PSO) cohorts, the psoriasis participants received placebo matching PF-06826647 400, or 100 mg QD PSO cohort for 28 days with standard meal. Psoriasis cohort duration was 84 days.', 'otherNumAtRisk': 14, 'deathsNumAtRisk': 14, 'otherNumAffected': 7, 'seriousNumAtRisk': 14, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG016', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, the psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.', 'otherNumAtRisk': 15, 'deathsNumAtRisk': 15, 'otherNumAffected': 12, 'seriousNumAtRisk': 15, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG017', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, the psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.', 'otherNumAtRisk': 11, 'deathsNumAtRisk': 11, 'otherNumAffected': 5, 'seriousNumAtRisk': 11, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Cerumen impaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Ear discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Abdominal discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Epigastric discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Faeces hard', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Face oedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Oedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Peripheral swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Secretion discharge', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Otitis externa', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Postoperative wound infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Viral upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Periorbital haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Periorbital haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Procedural pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Aspartate aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Blood creatine phosphokinase', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Blood creatinine increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 5, 'numAffected': 3}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Blood uric acid increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Body temperature', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Lymphocyte count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Sinus headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Dysuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Oropharyngeal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Rhinitis allergic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 4, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Rhinorrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Rash', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}, {'term': 'Urticaria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 13, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 9, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 2, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 8, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 6, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 7, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 5, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 14, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 15, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 11, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v21.1'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Number of Participants With Vital Signs Data Meeting Pre-Specified Criteria (Single Ascending Dose [SAD] Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'PBO SAD', 'description': 'During the SAD period (Period 1), healthy participants received placebo matching PF-06826647 3, 10, 30, 100, 400, or 1600 mg single dose (SD) cohort in fasted state. Participants in PBO SAD cohorts = participants in \\[PBO SAD (3mg, 10mg)\\] cohorts + participants in \\[PBO SAD -\\> PBO QD\\] cohorts.'}, {'id': 'OG001', 'title': 'PF-06826647 3 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.'}, {'id': 'OG002', 'title': 'PF-06826647 10 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.'}, {'id': 'OG003', 'title': 'PF-06826647 30 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.'}, {'id': 'OG004', 'title': 'PF-06826647 100 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.'}, {'id': 'OG005', 'title': 'PF-06826647 400 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.'}, {'id': 'OG006', 'title': 'PF-06826647 1600 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.'}], 'classes': [{'title': 'Supine diastolic BP Value <50 mmHg', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'Supine diastolic BP Change (Chg) ≥20 mmHg increase', 'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '2', 'groupId': 'OG006'}]}]}, {'title': 'Supine diastolic BP Chg ≥20 mmHg decrease', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'Supine pulse rate Value <40 beats per minute (bpm)', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'Supine pulse rate Value >120 bpm', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'Supine systolic BP Value <90mmHg', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'Supine systolic BP Chg ≥30 mmHg increase', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'Supine systolic BP Chg ≥30mmHg decrease', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Day 8', 'description': 'Maximum absolute values and changes from baseline for vital signs (for supine systolic/diastolic blood pressure \\[BP\\] and supine pulse rate \\[PR\\]) were summarized descriptively by treatment. Numbers of participants meeting the categorical criteria were provided.\n\nNumber of participants in PBO SAD cohorts = number of participants in \\[PBO SAD (3mg, 10mg)\\] cohorts + number of participants in \\[PBO SAD -\\> PBO QD MAD\\] cohorts.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the healthy participants who received study treatment and who had the safety parameters in the SAD Period. MAD and Psoriasis Cohorts data were not included.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Vital Signs Data Meeting Pre-Specified Criteria (Multiple Ascending Dose [MAD] Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'PBO QD MAD (JP PBO Included)', 'description': 'This arm includes both non-Japanese and Japanese participants. In MAD period (Period 2), the non-Japanese participants received placebo matching PF-06826647 30, 100, 400, or 1200 mg once daily (QD) cohort while the Japanese participants received placebo matching PF-06826647 400 mg QD Japanese cohort, both for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PBO BID', 'description': 'During the MAD period (Period 2), healthy participants received placebo matching PF-06826647 200 mg BID cohort with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}, {'id': 'OG006', 'title': 'PF-06826647 200 mg BID', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG007', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}], 'classes': [{'title': 'Supine diastolic BP Value < 50 mmHg', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '1', 'groupId': 'OG007'}]}]}, {'title': 'Supine diastolic BP Chg ≥ 20 mmHg increase', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Supine diastolic BP Chg ≥ 20 mmHg decrease', 'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '2', 'groupId': 'OG007'}]}]}, {'title': 'Supine pulse rate Value < 40 bpm', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Supine pulse rate Value > 120 bpm', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Supine systolic blood pressure Value < 90 mmHg', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '1', 'groupId': 'OG007'}]}]}, {'title': 'Supine systolic BP Chg ≥ 30 mmHg increase', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Supine systolic BP Chg ≥ 30 mmHg decrease', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Day 28', 'description': 'Maximum absolute values and changes from baseline for vital signs (for supine systolic/diastolic blood pressure and supine pulse rate) were summarized descriptively by treatment. Numbers of participants meeting the categorical criteria were provided.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the healthy participants who received study treatment in the MAD Period. The PBO QD MAD sequence is comprised of both non-Japanese and Japanese participants. The non-Japanese participants had completed the SAD period and continued into the MAD period. The Japanese participants took part only in the MAD period.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Vital Signs Data Meeting Pre-Specified Criteria (Psoriasis Cohorts)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'PBO QD PSO', 'description': 'In the psoriasis (PSO) cohorts, psoriasis participants received placebo matching PF-06826647 400, or 100 mg QD PSO cohort for 28 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}, {'id': 'OG002', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}], 'classes': [{'title': 'Supine diastolic blood pressure Value < 50 mmHg', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Supine diastolic BP Chg ≥ 20 mmHg increase', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}]}]}, {'title': 'Supine diastolic BP Chg ≥ 20 mmHg decrease', 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}]}]}, {'title': 'Supine pulse rate Value < 40 bpm', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Supine pulse rate Value > 120 bpm', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Supine systolic BP Value < 90 mmHg', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Supine systolic BP Chg ≥ 30 mmHg increase', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}]}, {'title': 'Supine systolic BP Chg ≥ 30 mmHg decrease', 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Day 56', 'description': 'Maximum absolute values and changes from baseline for vital signs (for supine systolic/diastolic blood pressure and supine pulse rate) were summarized descriptively by treatment. Numbers of participants meeting the categorical criteria were provided.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the psoriasis participants who received study treatment and who had the safety parameters in the Psoriasis Cohorts. Data in SAD/MAD Periods were not included.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Physical Examination Data Meeting Pre-Specified Criteria (SAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'PBO SAD', 'description': 'During the SAD period (Period 1), healthy participants received placebo matching PF-06826647 3, 10, 30, 100, 400, or 1600 mg single dose (SD) cohort in fasted state. Participants in PBO SAD cohorts = participants in \\[PBO SAD (3mg, 10mg)\\] cohorts + participants in \\[PBO SAD -\\> PBO QD\\] cohorts.'}, {'id': 'OG001', 'title': 'PF-06826647 3 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.'}, {'id': 'OG002', 'title': 'PF-06826647 10 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.'}, {'id': 'OG003', 'title': 'PF-06826647 30 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.'}, {'id': 'OG004', 'title': 'PF-06826647 100 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.'}, {'id': 'OG005', 'title': 'PF-06826647 400 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.'}, {'id': 'OG006', 'title': 'PF-06826647 1600 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.'}], 'classes': [{'title': 'cardiovascular', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'ears', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'eyes', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'gastrointestinal', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'general appearance', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'head', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'heart', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'lungs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'lymph nodes', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'mouth', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'musculoskeletal', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'neurological', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'nose', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'skin', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Day 8', 'description': "Physical examinations were conducted by a physician, trained physician assistant, or nurse practitioner as acceptable according to local regulation. A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Findings were considered to be clinically significant based on investigator's decision.\n\nNumber of participants in PBO SAD cohorts = number of participants in \\[PBO SAD (3mg, 10mg)\\] cohorts + number of participants in \\[PBO SAD -\\> PBO QD MAD\\] cohorts.", 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the healthy participants who received study treatment and who had the safety parameters in the SAD Period. MAD and Psoriasis Cohorts data were not included.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Physical Examination Data Meeting Pre-Specified Criteria (MAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'PBO QD MAD', 'description': 'This arm includes both non-Japanese and Japanese participants. In MAD period (Period 2), the non-Japanese participants received placebo matching PF-06826647 30, 100, 400, or 1200 mg once daily (QD) cohort while the Japanese participants received placebo matching PF-06826647 400 mg QD Japanese cohort, both for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PBO BID', 'description': 'During the MAD period (Period 2), healthy participants received placebo matching PF-06826647 200 mg BID cohort with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}, {'id': 'OG006', 'title': 'PF-06826647 200 mg BID', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG007', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}], 'classes': [{'title': 'cardiovascular', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'ears', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'eyes', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'gastrointestinal', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'general appearance', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'head', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'heart', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'lungs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'lymph nodes', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'mouth', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'musculoskeletal', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'neurological', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'nose', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'skin', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Day 28', 'description': "Physical examinations were conducted by a physician, trained physician assistant, or nurse practitioner as acceptable according to local regulation. A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Findings were considered to be clinically significant based on investigator's decision.", 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the healthy participants who received study treatment in the MAD Period. The PBO QD MAD sequence is comprised of both non-Japanese and Japanese participants. The non-Japanese participants had completed the SAD period and continued into the MAD period. The Japanese participants took part only in the MAD period.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Physical Examination Data Meeting Pre-Specified Criteria (Psoriasis Cohorts)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'PBO QD PSO', 'description': 'In the psoriasis (PSO) cohorts, psoriasis participants received placebo matching PF-06826647 400, or 100 mg QD PSO cohort for 28 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}, {'id': 'OG002', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}], 'classes': [{'title': 'cardiovascular', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'ears at screening', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'ears at Day 28', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'eyes', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'gastrointestinal', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'general appearance', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'head', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'heart', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'lungs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'lymph nodes', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'mouth', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'musculoskeletal', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'neurological', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'nose', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'skin', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Day 56', 'description': "Physical examinations were conducted by a physician, trained physician assistant, or nurse practitioner as acceptable according to local regulation. A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Findings were considered to be clinically significant based on investigator's decision.", 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the psoriasis participants who received study treatment and who had the safety parameters in the Psoriasis Cohorts. Data in SAD/MAD Periods were not included.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Electrocardiogram (ECG) Data Meeting Pre-Specified Criteria (SAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'PBO SAD', 'description': 'During the SAD period (Period 1), healthy participants received placebo matching PF-06826647 3, 10, 30, 100, 400, or 1600 mg single dose (SD) cohort in fasted state. Participants in PBO SAD cohorts = participants in \\[PBO SAD (3mg, 10mg)\\] cohorts + participants in \\[PBO SAD -\\> PBO QD\\] cohorts.'}, {'id': 'OG001', 'title': 'PF-06826647 3 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.'}, {'id': 'OG002', 'title': 'PF-06826647 10 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.'}, {'id': 'OG003', 'title': 'PF-06826647 30 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.'}, {'id': 'OG004', 'title': 'PF-06826647 100 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.'}, {'id': 'OG005', 'title': 'PF-06826647 400 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.'}, {'id': 'OG006', 'title': 'PF-06826647 1600 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.'}], 'classes': [{'title': 'PR maximum absolute value ≥300 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'PR maximum increase from baseline ≥25/50%', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'QRS maximum absolute value ≥140 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'QRS maximum increase from baseline ≥50%', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'QTCF maximum absolute value ≥450 and <480 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'QTCF maximum absolute value ≥480 and <500 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'QTCF maximum absolute value ≥500 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'QTCF maximum increase ≥30 and <60 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'QTCF maximum increase from baseline ≥60 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Day 8', 'description': 'ECG endpoints and changes from baseline (QTcF, PR and QRS) were summarized descriptively by cohort and treatment using pre-defined categories. Numbers of participants meeting the categorical criteria were provided. All planned and unplanned post-dose time points were counted in these categorical summaries. Categorical summarization criteria for ECG were as follows: 1) QTcF maximum absolute value ≥450 and \\<480 millisecond (msec), ≥480 and \\<500 msec. ≥500 msec; 2) QTcF maximum increase ≥30 and \\<60 msec, ≥60 msec; 3) PR maximum absolute value ≥300 msec; 4) PR maximum increases from baseline ≥25% if baseline \\>200 msec, ≥50% if baseline ≤200 msec; 5) QRS maximum absolute value ≥140 msec; 6) QRS maximum increase from baseline ≥50%.\n\nNumber of participants in PBO SAD cohorts = number of participants in \\[PBO SAD (3mg, 10mg)\\] cohorts + number of participants in \\[PBO SAD -\\> PBO QD MAD\\] cohorts.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the healthy participants who received study treatment and who had the safety parameters in the SAD Period. MAD and Psoriasis Cohorts data were not included.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With ECG Data Meeting Pre-Specified Criteria (MAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'PBO QD MAD', 'description': 'This arm includes both non-Japanese and Japanese participants. In MAD period (Period 2), the non-Japanese participants received placebo matching PF-06826647 30, 100, 400, or 1200 mg once daily (QD) cohort while the Japanese participants received placebo matching PF-06826647 400 mg QD Japanese cohort, both for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PBO BID', 'description': 'During the MAD period (Period 2), healthy participants received placebo matching PF-06826647 200 mg BID cohort with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}, {'id': 'OG006', 'title': 'PF-06826647 200 mg BID', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG007', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}], 'classes': [{'title': 'PR maximum absolute value ≥300 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'PR maximum increase from baseline ≥25/50%', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'QRS maximum absolute value ≥140 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'QRS maximum increase from baseline ≥50%', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'QTCF maximum absolute value ≥450 and <480 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '1', 'groupId': 'OG007'}]}]}, {'title': 'QTCF maximum absolute value ≥480 and <500 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'QTCF maximum absolute value ≥500 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'QTCF maximum increase ≥30 and <60 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'QTCF maximum increase from baseline ≥60 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Day 28', 'description': 'ECG endpoints and changes from baseline (QTcF, PR and QRS) were summarized descriptively by cohort and treatment using pre-defined categories. Numbers of participants meeting the categorical criteria were provided. All planned and unplanned post-dose time points were counted in these categorical summaries. Categorical summarization criteria for ECG were as follows: 1) QTcF maximum absolute value ≥450 and \\<480 millisecond (msec), ≥480 and \\<500 msec. ≥500 msec; 2) QTcF maximum increase ≥30 and \\<60 msec, ≥60 msec; 3) PR maximum absolute value ≥300 msec; 4) PR maximum increases from baseline ≥25% if baseline \\>200 msec, ≥50% if baseline ≤200 msec; 5) QRS maximum absolute value ≥140 msec; 6) QRS maximum increase from baseline ≥50%.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the healthy participants who received study treatment in the MAD Period. The PBO QD MAD sequence is comprised of both non-Japanese and Japanese participants. The non-Japanese participants had completed the SAD period and continued into the MAD period. The Japanese participants took part only in the MAD period.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With ECG Data Meeting Pre-Specified Criteria (Psoriasis Cohorts)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'PBO QD PSO', 'description': 'In the psoriasis (PSO) cohorts, psoriasis participants received placebo matching PF-06826647 400, or 100 mg QD PSO cohort for 28 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}, {'id': 'OG002', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}], 'classes': [{'title': 'PR maximum absolute value ≥300 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'PR maximum increase from baseline ≥25/50%', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'QRS maximum absolute value ≥140 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'QRS maximum increase from baseline ≥50%', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'QTCF maximum absolute value ≥450 and <480 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'QTCF maximum absolute value ≥480 and <500 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'QTCF maximum absolute value ≥500 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'QTCF maximum increase ≥30 and <60 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'QTCF maximum increase from baseline ≥60 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Day 56', 'description': 'ECG endpoints and changes from baseline (QTcF, PR and QRS) were summarized descriptively by cohort and treatment using pre-defined categories. Numbers of participants meeting the categorical criteria were provided. All planned and unplanned post-dose time points were counted in these categorical summaries. Categorical summarization criteria for ECG were as follows: 1) QTcF maximum absolute value ≥450 and \\<480 millisecond (msec), ≥480 and \\<500 msec. ≥500 msec; 2) QTcF maximum increase ≥30 and \\<60 msec, ≥60 msec; 3) PR maximum absolute value ≥300 msec; 4) PR maximum increases from baseline ≥25% if baseline \\>200 msec, ≥50% if baseline ≤200 msec; 5) QRS maximum absolute value ≥140 msec; 6) QRS maximum increase from baseline ≥50%.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the psoriasis participants who received study treatment and who had the safety parameters in the Psoriasis Cohorts. Data in SAD/MAD Periods were not included.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Who Withdrew Due to Adverse Events (AEs) (SAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'PBO SAD', 'description': 'During the SAD period (Period 1), healthy participants received placebo matching PF-06826647 3, 10, 30, 100, 400, or 1600 mg single dose (SD) cohort in fasted state. Participants in PBO SAD cohorts = participants in \\[PBO SAD (3mg, 10mg)\\] cohorts + participants in \\[PBO SAD -\\> PBO QD\\] cohorts.'}, {'id': 'OG001', 'title': 'PF-06826647 3 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.'}, {'id': 'OG002', 'title': 'PF-06826647 10 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.'}, {'id': 'OG003', 'title': 'PF-06826647 30 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.'}, {'id': 'OG004', 'title': 'PF-06826647 100 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.'}, {'id': 'OG005', 'title': 'PF-06826647 400 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.'}, {'id': 'OG006', 'title': 'PF-06826647 1600 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.'}], 'classes': [{'title': 'Participants with AEs (AC)', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '2', 'groupId': 'OG006'}]}]}, {'title': 'Participants with AEs (TR)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'Participants with SAEs (AC)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'Participants with SAEs (TR)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'Participants with severe AEs (AC)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'Participants with severe AEs (TR)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'Participants withdrew due to AEs (AC)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'Participants withdrew due to AEs (TR)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Day 8', 'description': 'An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. All events occurring following start of the treatment or increasing in severity were counted as treatment emergent. Events that occurred in a non-treatment period (eg, washout or follow-up) were counted as treatment emergent and attributed to the previous treatment taken. For each event, the investigator pursued and obtained adequate information both to determine the outcome and to assess whether it meets the criteria for classification as an SAE.\n\nPBO SAD cohorts = \\[PBO SAD (3mg, 10mg)\\] cohorts + \\[PBO SAD -\\> PBO QD MAD\\] cohorts.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the healthy participants who received study treatment and who had the safety parameters in the SAD Period. MAD and Psoriasis Cohorts data were not included.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With TEAEs, SAEs, and Who Withdrew Due to AEs (MAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'PBO QD MAD', 'description': 'This arm includes both non-Japanese and Japanese participants. In MAD period (Period 2), the non-Japanese participants received placebo matching PF-06826647 30, 100, 400, or 1200 mg once daily (QD) cohort while the Japanese participants received placebo matching PF-06826647 400 mg QD Japanese cohort, both for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PBO BID', 'description': 'During the MAD period (Period 2), healthy participants received placebo matching PF-06826647 200 mg BID cohort with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}, {'id': 'OG006', 'title': 'PF-06826647 200 mg BID', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG007', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}], 'classes': [{'title': 'Participants with AEs (AC)', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '3', 'groupId': 'OG006'}, {'value': '1', 'groupId': 'OG007'}]}]}, {'title': 'Participants with AEs (TR)', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '2', 'groupId': 'OG006'}, {'value': '1', 'groupId': 'OG007'}]}]}, {'title': 'Participants with SAEs (AC)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Participants with SAEs (TR)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Participants with severe AEs (AC)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Participants with severe AEs (TR)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Participants withdrew due to AEs (AC)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Participants withdrew due to AEs (TR)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Day 28', 'description': 'An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. All events occurring following start of the treatment or increasing in severity were counted as treatment emergent. Events that occurred in a non-treatment period (eg, washout or follow-up) were counted as treatment emergent and attributed to the previous treatment taken. For each event, the investigator pursued and obtained adequate information both to determine the outcome and to assess whether it meets the criteria for classification as an SAE.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the healthy participants who received study treatment in the MAD Period. The PBO QD MAD sequence is comprised of both non-Japanese and Japanese participants. The non-Japanese participants had completed the SAD period and continued into the MAD period. The Japanese participants took part only in the MAD period.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With TEAEs, SAEs, and Who Withdrew Due to AEs (Psoriasis Cohorts)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'PBO QD PSO', 'description': 'In the psoriasis (PSO) cohorts, psoriasis participants received placebo matching PF-06826647 400, or 100 mg QD PSO cohort for 28 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}, {'id': 'OG002', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}], 'classes': [{'title': 'Participants with AEs (AC)', 'categories': [{'measurements': [{'value': '7', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}]}]}, {'title': 'Participants with AEs (TR)', 'categories': [{'measurements': [{'value': '5', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}]}, {'title': 'Participants with SAEs (AC)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Participants with SAEs (TR)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Participants with severe AEs (AC)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Participants with severe AEs (TR)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Participants withdrew due to AEs (AC)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Participants withdrew due to AEs (TR)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Day 84', 'description': 'An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. All events occurring following start of the treatment or increasing in severity were counted as treatment emergent. Events that occurred in a non-treatment period (eg, washout or follow-up) were counted as treatment emergent and attributed to the previous treatment taken. For each event, the investigator pursued and obtained adequate information both to determine the outcome and to assess whether it meets the criteria for classification as an SAE.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the psoriasis participants who received study treatment and who had the safety parameters in the Psoriasis Cohorts. Data in SAD/MAD Periods were not included.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Laboratory Abnormalities (SAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'groups': [{'id': 'OG000', 'title': 'PBO SAD', 'description': 'During the SAD period (Period 1), healthy participants received placebo matching PF-06826647 3, 10, 30, 100, 400, or 1600 mg single dose (SD) cohort in fasted state. Participants in PBO SAD cohorts = participants in \\[PBO SAD (3mg, 10mg)\\] cohorts + participants in \\[PBO SAD -\\> PBO QD\\] cohorts.'}, {'id': 'OG001', 'title': 'PF-06826647 3 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.'}, {'id': 'OG002', 'title': 'PF-06826647 10 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.'}, {'id': 'OG003', 'title': 'PF-06826647 30 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.'}, {'id': 'OG004', 'title': 'PF-06826647 100 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.'}, {'id': 'OG005', 'title': 'PF-06826647 400 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.'}, {'id': 'OG006', 'title': 'PF-06826647 1600 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.'}], 'classes': [{'title': 'Ery. MCV (femtoliters [fL]) <0.9 × LLN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'Ery. MCH (picograms [pg]) <0.9 × LLN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'Reticulocytes/erythrocytes (%) >1.5 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'Limphocytes (10^3/mm^3) <0.8 × LLN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'Eosinophils (10^3/mm^3) >1.2 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}]}]}, {'title': 'Bilirubin (mg/dL) >1.5 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'AST (U/L) >3 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}]}]}, {'title': 'Urate (mg/dL) >1.2 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'HDL cholesterol (mg/dL) <0.8 × LLN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'LDL cholesterol (mg/dL) >1.2 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '10', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '4', 'groupId': 'OG006'}]}]}, {'title': 'Triglycerides (mg/dL) >1.3 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '2', 'groupId': 'OG005'}, {'value': '2', 'groupId': 'OG006'}]}]}, {'title': 'Cholesterol (mg/dL) >1.3 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'Ketones ≥1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'Nitrite ≥1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '2', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}]}]}, {'title': 'Leukocyte esterase ≥1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}, {'title': 'Epithelial cells (/LPF) ≥6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '2', 'groupId': 'OG005'}, {'value': '2', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}]}]}, {'title': 'Urinalysis-bacteria (/HPF) ≥20', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '2', 'groupId': 'OG005'}, {'value': '2', 'groupId': 'OG006'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Day 8', 'description': 'Laboratory data were listed and summarized by treatment in accordance with the sponsor reporting standards. Parameters for laboratory abnormalities evaluation included: erythrocyte mean corpuscular volume (Ery. MCV), erythrocyte mean corpuscular hemoglobin (Ery. MCH), reticulocytes/erythrocytes (%), limphocytes, eosinophils, bilirubin, aspartate aminotransferase (AST), urate, high-density lipoproteins (HDL) cholesterol, low-density lipoproteins (LDL) cholesterol, triglycerides, cholesterol, ketones, nitrite, leukocyte esterase, epithelial cells, urinalysis-bacteria.\n\nNumber of participants in PBO SAD cohorts = number of participants in \\[PBO SAD (3mg, 10mg)\\] cohorts + number of participants in \\[PBO SAD -\\> PBO QD MAD\\] cohorts.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the healthy participants who received study treatment and who had the safety parameters in the SAD Period. MAD and Psoriasis Cohorts data were not included.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Laboratory Abnormalities (MAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'PBO QD MAD', 'description': 'This arm includes both non-Japanese and Japanese participants. In MAD period (Period 2), the non-Japanese participants received placebo matching PF-06826647 30, 100, 400, or 1200 mg once daily (QD) cohort while the Japanese participants received placebo matching PF-06826647 400 mg QD Japanese cohort, both for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PBO BID', 'description': 'During the MAD period (Period 2), healthy participants received placebo matching PF-06826647 200 mg BID cohort with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}, {'id': 'OG006', 'title': 'PF-06826647 200 mg BID', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG007', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}], 'classes': [{'title': 'Ery. MCV (fL) <0.9 × LLN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Ery. MCH (pg) <0.9 × LLN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '1', 'groupId': 'OG007'}]}]}, {'title': 'Ery. MCH (pg) >1.1 × ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Reticulocytes/erythrocytes (%) >1.5 × ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Lymphocytes (10^3/mm^3) <0.8 × LLN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '1', 'groupId': 'OG007'}]}]}, {'title': 'Lymphocytes (10^3/mm^3) >1.2 × ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Neutrophils (10^3/mm^3) <0.8 × LLN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Eosinophils (10^3/mm^3) >1.2 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Bilirubin (mg/dL) >1.5 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Urate (mg/dL) >1.2 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'HDL cholesterol (mg/dL) <0.8 × LLN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'LDL cholesterol (mg/dL) >1.2 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '7', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '4', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}]}, {'title': 'Triglycerides (mg/dL) >1.3 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '2', 'groupId': 'OG007'}]}]}, {'title': 'Bicarbonate (mEq/L) >1.1 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '2', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'cholesterol (mg/dL) >1.3 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '2', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Urine glucose ≥1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Urine hemoglobin ≥1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Nitrite ≥1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Leukocyte esterase ≥1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '7', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Epithelial cells (/LPF) ≥6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '1', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Urinalysis-casts (/LPF) >1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '1', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Urinalysis-bacteria (/HPF) >20', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '1', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'Urine 24 hours creatinine (mg/24 hr) >1.1 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Day 28', 'description': 'Laboratory data were listed and summarized by treatment in accordance with the sponsor reporting standards. Parameters and corresponding primary criteria for laboratory abnormalities evaluation included: Ery. MCV \\<0.9 × LLN, Ery. Mean corpuscular hemoglobin (Ery. MCH) \\<0.9 × LLN or \\>1.1 ULN, reticulocytes/erythrocytes (%) \\>1.5 × ULN, lymphocytes \\<0.8 × LLN or \\>1.2 × ULN, neutrophils \\<0.8 × LLN, eosinophils \\>1.2 × ULN, bilirubin \\>1.5 × ULN, urate \\>1.2 × ULN, HDL cholesterol \\<0.8 × LLN, LDL cholesterol \\>1.2 × ULN, triglycerides \\>1.3 × ULN, bicarbonate \\>1.1 × ULN, cholesterol \\>1.3 × ULN, urine glucose ≥1, urine hemoglobin ≥1, nitrite ≥1, leukocyte esterase ≥1, epithelial cells ≥6/LPF, urinalysis-casts \\>1/LPF, urinalysis-bacteria \\>20/HPF, urine 24 hours creatinine \\>1.1 × ULN.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the healthy participants who received study treatment in the MAD Period. The PBO QD MAD sequence is comprised of both non-Japanese and Japanese participants. The non-Japanese participants had completed the SAD period and continued into the MAD period. The Japanese participants took part only in the MAD period.'}, {'type': 'PRIMARY', 'title': 'Number of Participants With Laboratory Abnormalities (Psoriasis Cohorts)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'PBO QD PSO', 'description': 'In the psoriasis (PSO) cohorts, psoriasis participants received placebo matching PF-06826647 400, or 100 mg QD PSO cohort for 28 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}, {'id': 'OG002', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}], 'classes': [{'title': 'Reticulocytes/erythrocytes (%) >1.5 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Lymphocytes (10^3/mm^3) <0.8 x LLN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Neutrophils (10^3/mm^3) <0.8 x LLN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Neutrophils (10^3/mm^3) >1.2 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Eosinophils (10^3/mm^3) >1.2 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Bilirubin (mg/dL) >1.5 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'ALT (U/L) >3 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Creatinine (mg/dL) >1.3 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Urate (mg/dL) >1.2 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '7', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}]}, {'title': 'HDL cholesterol (mg/dL) <0.8 x LLN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'LDL cholesterol (mg/dL) >1.2 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '11', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}]}]}, {'title': 'Triglycerides (mg/dL) >1.3 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}]}, {'title': 'Potassium (mEq/L) >1.1 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Bicarbonate (mEq/L) >1.1 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Glucose (mg/dL) <0.6 x LLN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Glucose (mg/dL) >1.5 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'CK (U/L) >2 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}]}, {'title': 'cholesterol (mg/dL) >1.3 x ULN', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Urine glucose ≥1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Ketones ≥1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Urine hemoglobin ≥1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}]}]}, {'title': 'Urine bilirubin ≥1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Leukocyte esterase ≥1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Epithelial cells (/LPF) ≥6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Urinalysis-bacteria (/HPF) >20', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline up to Day 56', 'description': 'Laboratory data were listed and summarized by treatment in accordance with the sponsor reporting standards. Parameters and corresponding primary criteria for laboratory abnormalities evaluation included: reticulocytes/erythrocytes (%) \\>1.5 × ULN, lymphocytes \\<0.8 × LLN, neutrophils \\<0.8 × LLN or \\>1.2 × ULN, eosinophils \\>1.2 × ULN, bilirubin \\>1.5 × ULN, alanine aminotransferase (ALT) \\>3.0 × ULN, creatinine \\>1.3 × ULN, urate \\>1.2 × ULN, HDL cholesterol \\<0.8 × LLN, LDL cholesterol \\>1.2 × ULN, triglycerides \\>1.3 × ULN, potassium \\>1.1 × ULN, bicarbonate \\>1.1 × ULN, glucose \\<0.6 × LLN or \\>1.5 × ULN, Creatine Kinase (CK) \\>2.0 × ULN, cholesterol \\>1.3 × ULN, urine glucose ≥1, ketones ≥1, urine hemoglobin ≥1, urine bilirubin ≥1, leukocyte esterase ≥1, epithelial cells ≥6/LPF, urinalysis-bacteria/HPF.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the psoriasis participants who received study treatment and who had the safety parameters in the Psoriasis Cohorts. Data in SAD/MAD Periods were not included.'}, {'type': 'PRIMARY', 'title': 'Change in 24 Hour Creatinine Clearance From Day -1 on Day 10 (MAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '5', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}, {'value': '6', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'PBO QD MAD', 'description': 'This arm includes both non-Japanese and Japanese participants. In MAD period (Period 2), the non-Japanese participants received placebo matching PF-06826647 30, 100, 400, or 1200 mg once daily (QD) cohort while the Japanese participants received placebo matching PF-06826647 400 mg QD Japanese cohort, both for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PBO BID', 'description': 'During the MAD period (Period 2), healthy participants received placebo matching PF-06826647 200 mg BID cohort with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}, {'id': 'OG006', 'title': 'PF-06826647 200 mg BID', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG007', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '-21.0', 'spread': '98.76', 'groupId': 'OG000'}, {'value': '-32.0', 'spread': 'NA', 'comment': 'One (1) participant was analyzed, so standard deviation did not exist.', 'groupId': 'OG001'}, {'value': '-62.4', 'spread': '45.10', 'groupId': 'OG002'}, {'value': '0.2', 'spread': '65.64', 'groupId': 'OG003'}, {'value': '-52.5', 'spread': '56.22', 'groupId': 'OG004'}, {'value': '-11.4', 'spread': '58.76', 'groupId': 'OG005'}, {'value': '-64.7', 'spread': '36.22', 'groupId': 'OG006'}, {'value': '40.2', 'spread': '45.26', 'groupId': 'OG007'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day -1 and Day 10', 'description': 'Change in 24-hour creatinine clearance at Day 10 from Day -1 (baseline) during the MAD was presented by treatment group.', 'unitOfMeasure': 'milliliters per minute (mL/min)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the healthy participants who received study treatment in the MAD Period. The PBO QD MAD sequence is comprised of both non-Japanese and Japanese participants. The non-Japanese participants had completed the SAD period and continued into the MAD period. The Japanese participants took part only in the MAD period.'}, {'type': 'SECONDARY', 'title': 'Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) (SAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '4', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 3 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.'}, {'id': 'OG001', 'title': 'PF-06826647 10 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.'}, {'id': 'OG002', 'title': 'PF-06826647 30 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.'}, {'id': 'OG003', 'title': 'PF-06826647 100 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.'}, {'id': 'OG005', 'title': 'PF-06826647 1600 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.'}], 'classes': [{'categories': [{'measurements': [{'value': '47.63', 'spread': '59', 'groupId': 'OG000'}, {'value': '369.3', 'spread': '67', 'groupId': 'OG001'}, {'value': '848.4', 'spread': '40', 'groupId': 'OG002'}, {'value': '1582', 'spread': '42', 'groupId': 'OG003'}, {'value': '3056', 'spread': '65', 'groupId': 'OG004'}, {'value': '11790', 'spread': '25', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 'AUCinf = Area under the plasma concentration versus time curve (AUC) from time 0 (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).', 'unitOfMeasure': 'nanograms*hours per mL (ng*hr/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.'}, {'type': 'SECONDARY', 'title': 'Secondary: Dose Normalized AUCinf (AUCinf[dn]) (SAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '4', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 3 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.'}, {'id': 'OG001', 'title': 'PF-06826647 10 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.'}, {'id': 'OG002', 'title': 'PF-06826647 30 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.'}, {'id': 'OG003', 'title': 'PF-06826647 100 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.'}, {'id': 'OG005', 'title': 'PF-06826647 1600 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.'}], 'classes': [{'categories': [{'measurements': [{'value': '15.86', 'spread': '59', 'groupId': 'OG000'}, {'value': '36.93', 'spread': '67', 'groupId': 'OG001'}, {'value': '28.28', 'spread': '41', 'groupId': 'OG002'}, {'value': '15.82', 'spread': '42', 'groupId': 'OG003'}, {'value': '7.636', 'spread': '65', 'groupId': 'OG004'}, {'value': '7.370', 'spread': '25', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 'AUCinf = Area under the plasma concentration versus time curve (AUC) from time 0 (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf). AUCinf(dn) = AUCinf / dose. Dose normalized AUC values of PF-06826647 was plotted against dose and included individual participant values and the geometric means for each dose. These plots were used to help understand the relationship between the plasma PK parameters and dose.', 'unitOfMeasure': 'ng*hr/mL/mg', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.'}, {'type': 'SECONDARY', 'title': 'Area Under the Concentration-Time Profile From Time 0 to 24 Hours (AUC24) (SAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 3 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.'}, {'id': 'OG001', 'title': 'PF-06826647 10 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.'}, {'id': 'OG002', 'title': 'PF-06826647 30 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.'}, {'id': 'OG003', 'title': 'PF-06826647 100 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.'}, {'id': 'OG005', 'title': 'PF-06826647 1600 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.'}], 'classes': [{'categories': [{'measurements': [{'value': '43.10', 'spread': '56', 'groupId': 'OG000'}, {'value': '347.8', 'spread': '62', 'groupId': 'OG001'}, {'value': '543.2', 'spread': '49', 'groupId': 'OG002'}, {'value': '1158', 'spread': '55', 'groupId': 'OG003'}, {'value': '2519', 'spread': '67', 'groupId': 'OG004'}, {'value': '9318', 'spread': '34', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'AUC24 was summarized by dosing regimen and period. It was determined by linear/log trapezoidal method.', 'unitOfMeasure': 'ng*hr/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.'}, {'type': 'SECONDARY', 'title': 'Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) (SAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 3 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.'}, {'id': 'OG001', 'title': 'PF-06826647 10 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.'}, {'id': 'OG002', 'title': 'PF-06826647 30 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.'}, {'id': 'OG003', 'title': 'PF-06826647 100 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.'}, {'id': 'OG005', 'title': 'PF-06826647 1600 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.'}], 'classes': [{'categories': [{'measurements': [{'value': '40.25', 'spread': '56', 'groupId': 'OG000'}, {'value': '354.8', 'spread': '67', 'groupId': 'OG001'}, {'value': '638.5', 'spread': '58', 'groupId': 'OG002'}, {'value': '1375', 'spread': '53', 'groupId': 'OG003'}, {'value': '2767', 'spread': '65', 'groupId': 'OG004'}, {'value': '9921', 'spread': '32', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 'AUClast was summarized by dosing regimen and period. It was determined by linear/log trapezoidal method.', 'unitOfMeasure': 'ng*hr/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.'}, {'type': 'SECONDARY', 'title': 'Dose Normalized AUClast (AUClast[dn]) (SAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 3 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.'}, {'id': 'OG001', 'title': 'PF-06826647 10 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.'}, {'id': 'OG002', 'title': 'PF-06826647 30 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.'}, {'id': 'OG003', 'title': 'PF-06826647 100 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.'}, {'id': 'OG005', 'title': 'PF-06826647 1600 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.'}], 'classes': [{'categories': [{'measurements': [{'value': '13.40', 'spread': '56', 'groupId': 'OG000'}, {'value': '35.48', 'spread': '67', 'groupId': 'OG001'}, {'value': '21.28', 'spread': '58', 'groupId': 'OG002'}, {'value': '13.75', 'spread': '53', 'groupId': 'OG003'}, {'value': '6.919', 'spread': '65', 'groupId': 'OG004'}, {'value': '6.200', 'spread': '32', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 'AUClast(dn) = AUClast / dose. Dose normalized AUC values of PF-06826647 were plotted against dose and included individual participant values and the geometric means for each dose. These plots was used to help understand the relationship between the plasma PK parameters and dose.', 'unitOfMeasure': 'ng*hr/mL/mg', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.'}, {'type': 'SECONDARY', 'title': 'Maximum Plasma Concentration (Cmax) (SAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 3 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.'}, {'id': 'OG001', 'title': 'PF-06826647 10 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.'}, {'id': 'OG002', 'title': 'PF-06826647 30 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.'}, {'id': 'OG003', 'title': 'PF-06826647 100 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.'}, {'id': 'OG005', 'title': 'PF-06826647 1600 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.'}], 'classes': [{'categories': [{'measurements': [{'value': '7.844', 'spread': '38', 'groupId': 'OG000'}, {'value': '47.09', 'spread': '35', 'groupId': 'OG001'}, {'value': '77.93', 'spread': '34', 'groupId': 'OG002'}, {'value': '166.8', 'spread': '55', 'groupId': 'OG003'}, {'value': '404.8', 'spread': '62', 'groupId': 'OG004'}, {'value': '1218', 'spread': '25', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 'Cmax was summarized by dosing regimen and period. It was observed directly from data.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.'}, {'type': 'SECONDARY', 'title': 'Dose Normalized Cmax (Cmax[dn]) (SAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 3 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.'}, {'id': 'OG001', 'title': 'PF-06826647 10 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.'}, {'id': 'OG002', 'title': 'PF-06826647 30 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.'}, {'id': 'OG003', 'title': 'PF-06826647 100 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.'}, {'id': 'OG005', 'title': 'PF-06826647 1600 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.617', 'spread': '38', 'groupId': 'OG000'}, {'value': '4.709', 'spread': '35', 'groupId': 'OG001'}, {'value': '2.597', 'spread': '34', 'groupId': 'OG002'}, {'value': '1.668', 'spread': '55', 'groupId': 'OG003'}, {'value': '1.012', 'spread': '62', 'groupId': 'OG004'}, {'value': '0.7618', 'spread': '25', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 'Cmax(dn) = Cmax / dose. To assess the relationship between Cmax and dose, dose normalized Cmax was plotted against dose, and included individual participant values and the geometric means for each dose.', 'unitOfMeasure': 'ng/mL/mg', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received the study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.'}, {'type': 'SECONDARY', 'title': 'Time for Cmax (Tmax) (SAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 3 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.'}, {'id': 'OG001', 'title': 'PF-06826647 10 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.'}, {'id': 'OG002', 'title': 'PF-06826647 30 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.'}, {'id': 'OG003', 'title': 'PF-06826647 100 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.'}, {'id': 'OG005', 'title': 'PF-06826647 1600 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.00', 'groupId': 'OG000', 'lowerLimit': '1.00', 'upperLimit': '2.00'}, {'value': '2.00', 'groupId': 'OG001', 'lowerLimit': '1.00', 'upperLimit': '4.00'}, {'value': '2.00', 'groupId': 'OG002', 'lowerLimit': '1.00', 'upperLimit': '4.00'}, {'value': '2.00', 'groupId': 'OG003', 'lowerLimit': '2.00', 'upperLimit': '6.00'}, {'value': '2.00', 'groupId': 'OG004', 'lowerLimit': '0.500', 'upperLimit': '4.00'}, {'value': '2.00', 'groupId': 'OG005', 'lowerLimit': '0.500', 'upperLimit': '4.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 'Tmax was summarized by dosing regimen and period. It was observed directly from data as time of first occurrence.', 'unitOfMeasure': 'hours (hr)', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received the study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.'}, {'type': 'SECONDARY', 'title': 'Terminal Elimination Half-Life ((t½) (SAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '4', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 3 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.'}, {'id': 'OG001', 'title': 'PF-06826647 10 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.'}, {'id': 'OG002', 'title': 'PF-06826647 30 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.'}, {'id': 'OG003', 'title': 'PF-06826647 100 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.'}, {'id': 'OG005', 'title': 'PF-06826647 1600 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.620', 'spread': '1.2956', 'groupId': 'OG000'}, {'value': '6.032', 'spread': '1.9050', 'groupId': 'OG001'}, {'value': '19.69', 'spread': '9.5144', 'groupId': 'OG002'}, {'value': '38.77', 'spread': '35.966', 'groupId': 'OG003'}, {'value': '16.25', 'spread': '9.3430', 'groupId': 'OG004'}, {'value': '22.21', 'spread': '24.586', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 't1/2 was summarized by dosing regimen and period. It was determined by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.', 'unitOfMeasure': 'hours (hr)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.'}, {'type': 'SECONDARY', 'title': 'Mean Residence Time (MRT) (SAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '4', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 3 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.'}, {'id': 'OG001', 'title': 'PF-06826647 10 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.'}, {'id': 'OG002', 'title': 'PF-06826647 30 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.'}, {'id': 'OG003', 'title': 'PF-06826647 100 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.'}, {'id': 'OG005', 'title': 'PF-06826647 1600 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.'}], 'classes': [{'categories': [{'measurements': [{'value': '5.596', 'spread': '26', 'groupId': 'OG000'}, {'value': '7.761', 'spread': '30', 'groupId': 'OG001'}, {'value': '16.97', 'spread': '43', 'groupId': 'OG002'}, {'value': '21.23', 'spread': '81', 'groupId': 'OG003'}, {'value': '10.56', 'spread': '36', 'groupId': 'OG004'}, {'value': '9.417', 'spread': '33', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 'MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from time 0 to infinity.', 'unitOfMeasure': 'hours (hr)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received the study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.'}, {'type': 'SECONDARY', 'title': 'Apparent Volume of Distribution (Vz/F) (SAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '4', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 3 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.'}, {'id': 'OG001', 'title': 'PF-06826647 10 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.'}, {'id': 'OG002', 'title': 'PF-06826647 30 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.'}, {'id': 'OG003', 'title': 'PF-06826647 100 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.'}, {'id': 'OG005', 'title': 'PF-06826647 1600 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.'}], 'classes': [{'categories': [{'measurements': [{'value': '312.1', 'spread': '34', 'groupId': 'OG000'}, {'value': '226.1', 'spread': '41', 'groupId': 'OG001'}, {'value': '902.9', 'spread': '81', 'groupId': 'OG002'}, {'value': '2671', 'spread': '134', 'groupId': 'OG003'}, {'value': '2732', 'spread': '128', 'groupId': 'OG004'}, {'value': '2877', 'spread': '146', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 'Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.', 'unitOfMeasure': 'liters (L)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.'}, {'type': 'SECONDARY', 'title': 'Apparent Clearance (CL/F) (SAD Period)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}, {'value': '7', 'groupId': 'OG004'}, {'value': '4', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 3 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.'}, {'id': 'OG001', 'title': 'PF-06826647 10 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.'}, {'id': 'OG002', 'title': 'PF-06826647 30 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.'}, {'id': 'OG003', 'title': 'PF-06826647 100 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.'}, {'id': 'OG005', 'title': 'PF-06826647 1600 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.'}], 'classes': [{'categories': [{'measurements': [{'value': '62.98', 'spread': '59', 'groupId': 'OG000'}, {'value': '27.08', 'spread': '67', 'groupId': 'OG001'}, {'value': '35.36', 'spread': '41', 'groupId': 'OG002'}, {'value': '63.21', 'spread': '42', 'groupId': 'OG003'}, {'value': '130.8', 'spread': '65', 'groupId': 'OG004'}, {'value': '135.4', 'spread': '26', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 'CL/F is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.', 'unitOfMeasure': 'liters per hour (L/hr)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.'}, {'type': 'SECONDARY', 'title': 'Area Under the Plasma Concentration-Time Profile Over the Dosing Interval τ (AUCτ) (MAD Period Day 1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '662.8', 'spread': '25', 'groupId': 'OG000'}, {'value': '1803', 'spread': '23', 'groupId': 'OG001'}, {'value': '1646', 'spread': '70', 'groupId': 'OG002'}, {'value': '4424', 'spread': '67', 'groupId': 'OG003'}, {'value': '6038', 'spread': '29', 'groupId': 'OG004'}, {'value': '17090', 'spread': '20', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'AUCτ was summarized by dosing regimen and period. Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval was 24 hours for QD dosing and 12 hours for BID dosing. It was determined by linear/log trapezoidal method.', 'unitOfMeasure': 'ng*hr/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'Dose Normalized AUCτ (AUCτ[dn]) (MAD Period Day 1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '22.10', 'spread': '25', 'groupId': 'OG000'}, {'value': '18.03', 'spread': '23', 'groupId': 'OG001'}, {'value': '8.229', 'spread': '70', 'groupId': 'OG002'}, {'value': '11.07', 'spread': '67', 'groupId': 'OG003'}, {'value': '15.10', 'spread': '29', 'groupId': 'OG004'}, {'value': '14.23', 'spread': '20', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Area Under the Plasma Concentration-Time Profile over the Dosing interval τ (AUCτ). Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing.\n\nAUCτ(dn) = AUCτ / Dose. To assess the relationship between the PK parameters and the dose, dose normalized AUCτ was plotted against dose, and included individual participant values and the geometric means for each dose.', 'unitOfMeasure': 'ng*hr/mL/mg', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'Cmax (MAD Period Day 1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '83.53', 'spread': '24', 'groupId': 'OG000'}, {'value': '267.2', 'spread': '20', 'groupId': 'OG001'}, {'value': '289.8', 'spread': '67', 'groupId': 'OG002'}, {'value': '585.9', 'spread': '33', 'groupId': 'OG003'}, {'value': '695.5', 'spread': '19', 'groupId': 'OG004'}, {'value': '2023', 'spread': '10', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Cmax was summarized by dosing regimen and period. It was observed directly from data.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'Cmax(dn) (MAD Period Day 1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.787', 'spread': '24', 'groupId': 'OG000'}, {'value': '2.672', 'spread': '20', 'groupId': 'OG001'}, {'value': '1.450', 'spread': '67', 'groupId': 'OG002'}, {'value': '1.468', 'spread': '33', 'groupId': 'OG003'}, {'value': '1.741', 'spread': '19', 'groupId': 'OG004'}, {'value': '1.686', 'spread': '10', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Cmax(dn) = Cmax / dose. To assess the relationship between Cmax and dose, dose normalized Cmax was plotted against dose, and included individual participant values and the geometric means for each dose.', 'unitOfMeasure': 'ng/mL/mg', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'Tmax (MAD Period Day 1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.00', 'groupId': 'OG000', 'lowerLimit': '2.00', 'upperLimit': '6.00'}, {'value': '4.00', 'groupId': 'OG001', 'lowerLimit': '1.00', 'upperLimit': '4.00'}, {'value': '4.00', 'groupId': 'OG002', 'lowerLimit': '2.00', 'upperLimit': '6.00'}, {'value': '3.00', 'groupId': 'OG003', 'lowerLimit': '2.00', 'upperLimit': '6.00'}, {'value': '4.00', 'groupId': 'OG004', 'lowerLimit': '2.00', 'upperLimit': '4.00'}, {'value': '2.00', 'groupId': 'OG005', 'lowerLimit': '2.00', 'upperLimit': '4.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Tmax was summarized by dosing regimen and period. It was observed directly from data as time of first occurrence.', 'unitOfMeasure': 'hours (hr)', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'AUCτ (MAD Period Day 10)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '752.9', 'spread': '32', 'groupId': 'OG000'}, {'value': '1952', 'spread': '33', 'groupId': 'OG001'}, {'value': '2010', 'spread': '49', 'groupId': 'OG002'}, {'value': '5420', 'spread': '57', 'groupId': 'OG003'}, {'value': '7194', 'spread': '20', 'groupId': 'OG004'}, {'value': '14890', 'spread': '31', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'AUCτ was summarized by dosing regimen and period. Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval was 24 hours for QD dosing and 12 hours for BID dosing. It was determined by linear/log trapezoidal method.', 'unitOfMeasure': 'ng*hr/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'AUCτ(dn) (MAD Period Day 10)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '25.06', 'spread': '32', 'groupId': 'OG000'}, {'value': '19.52', 'spread': '33', 'groupId': 'OG001'}, {'value': '10.04', 'spread': '49', 'groupId': 'OG002'}, {'value': '13.56', 'spread': '57', 'groupId': 'OG003'}, {'value': '18.00', 'spread': '19', 'groupId': 'OG004'}, {'value': '12.41', 'spread': '31', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Area Under the Plasma Concentration-Time Profile over the Dosing interval τ (AUCτ). Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing.\n\nAUCτ(dn) = AUCτ / Dose. To assess the relationship between the PK parameters and the dose, dose normalized AUCτ was plotted against dose, and included individual participant values and the geometric means for each dose.', 'unitOfMeasure': 'ng*hr/mL/mg', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'Cmax (MAD Period Day 10)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '85.34', 'spread': '27', 'groupId': 'OG000'}, {'value': '263.2', 'spread': '30', 'groupId': 'OG001'}, {'value': '339.5', 'spread': '46', 'groupId': 'OG002'}, {'value': '667.3', 'spread': '37', 'groupId': 'OG003'}, {'value': '887.0', 'spread': '11', 'groupId': 'OG004'}, {'value': '1855', 'spread': '21', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Cmax was summarized by dosing regimen and period. It was observed directly from data.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'Cmax(dn) (MAD Period Day 10)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.844', 'spread': '27', 'groupId': 'OG000'}, {'value': '2.632', 'spread': '30', 'groupId': 'OG001'}, {'value': '1.701', 'spread': '46', 'groupId': 'OG002'}, {'value': '1.669', 'spread': '37', 'groupId': 'OG003'}, {'value': '2.220', 'spread': '11', 'groupId': 'OG004'}, {'value': '1.547', 'spread': '21', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Cmax(dn) = Cmax / dose. To assess the relationship between Cmax and dose, dose normalized Cmax was plotted against dose, and included individual participant values and the geometric means for each dose.', 'unitOfMeasure': 'ng/mL/mg', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'Tmax (MAD Period Day 10)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '4.00', 'groupId': 'OG000', 'lowerLimit': '4.00', 'upperLimit': '6.00'}, {'value': '4.00', 'groupId': 'OG001', 'lowerLimit': '2.00', 'upperLimit': '4.00'}, {'value': '4.00', 'groupId': 'OG002', 'lowerLimit': '2.00', 'upperLimit': '4.00'}, {'value': '4.00', 'groupId': 'OG003', 'lowerLimit': '2.00', 'upperLimit': '6.00'}, {'value': '4.00', 'groupId': 'OG004', 'lowerLimit': '2.00', 'upperLimit': '6.00'}, {'value': '4.00', 'groupId': 'OG005', 'lowerLimit': '2.00', 'upperLimit': '4.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Tmax was summarized by dosing regimen and period. It was observed directly from data as time of first occurrence.', 'unitOfMeasure': 'hours (hr)', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'Average Concentration at Steady State (Cav) (MAD Period Day 10)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '31.36', 'spread': '32', 'groupId': 'OG000'}, {'value': '81.28', 'spread': '34', 'groupId': 'OG001'}, {'value': '167.6', 'spread': '49', 'groupId': 'OG002'}, {'value': '226.0', 'spread': '57', 'groupId': 'OG003'}, {'value': '299.7', 'spread': '20', 'groupId': 'OG004'}, {'value': '619.9', 'spread': '31', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': "Cav = AUCτ,ss / τ, where ss means 'at steady state', and where the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing. Cav was summarized by dosing regimen and period.", 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'Lowest Concentration Observed During the Dosing Interval τ (Cmin) (MAD Period Day 10)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.273', 'spread': '83', 'groupId': 'OG000'}, {'value': '10.40', 'spread': '75', 'groupId': 'OG001'}, {'value': '55.01', 'spread': '65', 'groupId': 'OG002'}, {'value': '24.77', 'spread': '148', 'groupId': 'OG003'}, {'value': '29.50', 'spread': '60', 'groupId': 'OG004'}, {'value': '62.26', 'spread': '112', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Cmin was observed directly from data. It was summarized by dosing regimen and period. Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'Terminal Elimination Half-Life ((t½) (MAD Period Day 10)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '8.802', 'spread': '5.8142', 'groupId': 'OG000'}, {'value': '12.72', 'spread': '12.644', 'groupId': 'OG001'}, {'value': '26.93', 'spread': '8.1132', 'groupId': 'OG002'}, {'value': '7.500', 'spread': '2.5803', 'groupId': 'OG003'}, {'value': '7.433', 'spread': '4.7975', 'groupId': 'OG004'}, {'value': '34.33', 'spread': '21.926', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24,48,72,96,168 hours post-dose', 'description': 't1/2 was summarized by dosing regimen and period. It was determined by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.', 'unitOfMeasure': 'hours (hr)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'MRT (MAD Period Day 10)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '10.56', 'spread': '44', 'groupId': 'OG000'}, {'value': '9.872', 'spread': '33', 'groupId': 'OG001'}, {'value': '17.14', 'spread': '26', 'groupId': 'OG002'}, {'value': '9.622', 'spread': '26', 'groupId': 'OG003'}, {'value': '7.996', 'spread': '19', 'groupId': 'OG004'}, {'value': '9.165', 'spread': '24', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24,48,72,96,168 hours post-dose', 'description': 'MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from time 0 to infinity.', 'unitOfMeasure': 'hours (hr)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'Peak Trough Ratio (PTR) (MAD Period Day 10)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '13.61', 'spread': '69', 'groupId': 'OG000'}, {'value': '25.31', 'spread': '55', 'groupId': 'OG001'}, {'value': '6.951', 'spread': '23', 'groupId': 'OG002'}, {'value': '26.92', 'spread': '112', 'groupId': 'OG003'}, {'value': '30.09', 'spread': '61', 'groupId': 'OG004'}, {'value': '29.76', 'spread': '97', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': "PTR = Cmax,ss / Cmin,ss, where ss means 'at steady state'. It was summarized by dosing regimen and period.", 'unitOfMeasure': 'ratio', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'Observed Accumulation Ratio Based on AUC (Rac) (MAD Period Day 10)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.085', 'spread': '8', 'groupId': 'OG000'}, {'value': '1.082', 'spread': '21', 'groupId': 'OG001'}, {'value': '1.328', 'spread': '52', 'groupId': 'OG002'}, {'value': '1.225', 'spread': '39', 'groupId': 'OG003'}, {'value': '1.191', 'spread': '24', 'groupId': 'OG004'}, {'value': '0.8711', 'spread': '30', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': "Rac = AUCτ,ss / AUCτ,sd, where ss means 'at steady state' and sd 'single dose'. In this study, Rac = AUCτ(Day 10) / AUCτ(Day 1). Rac was summarized by dosing regimen and period.", 'unitOfMeasure': 'ratio', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'Observed Accumulation Ratio Based on Cmax (Rac,Cmax) (MAD Period Day 10)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.9295', 'spread': '22', 'groupId': 'OG000'}, {'value': '0.9852', 'spread': '24', 'groupId': 'OG001'}, {'value': '1.282', 'spread': '57', 'groupId': 'OG002'}, {'value': '1.139', 'spread': '35', 'groupId': 'OG003'}, {'value': '1.275', 'spread': '14', 'groupId': 'OG004'}, {'value': '0.9176', 'spread': '25', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Days 1 and 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': "Rac,Cmax = Cmax,ss / Cmax,sd, where ss means 'at steady state' and sd 'single dose'. In this study, Rac,Cmax = Cmax(Day10) / Cmax(Day 1). Rac,Cmax was summarized by dosing regimen and period.", 'unitOfMeasure': 'ratio', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'Vz/F (MAD Period Day 10)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '433.5', 'spread': '52', 'groupId': 'OG000'}, {'value': '643.6', 'spread': '98', 'groupId': 'OG001'}, {'value': '3224', 'spread': '90', 'groupId': 'OG002'}, {'value': '758.9', 'spread': '93', 'groupId': 'OG003'}, {'value': '519.2', 'spread': '67', 'groupId': 'OG004'}, {'value': '2944', 'spread': '166', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.', 'unitOfMeasure': 'liters (L)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'CL/F (MAD Period Day 10)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '39.86', 'spread': '32', 'groupId': 'OG000'}, {'value': '51.27', 'spread': '34', 'groupId': 'OG001'}, {'value': '99.47', 'spread': '49', 'groupId': 'OG002'}, {'value': '73.78', 'spread': '57', 'groupId': 'OG003'}, {'value': '55.62', 'spread': '20', 'groupId': 'OG004'}, {'value': '80.63', 'spread': '31', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'CL/F is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.', 'unitOfMeasure': 'liters per hour (L/hr)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'Cumulative Amount of Drug Recovered Unchanged in Urine From Time 0 to the Dosing Interval τ Hours Post-Dose (Aeτ) (MAD Period Day 10)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.2204', 'spread': '35', 'groupId': 'OG000'}, {'value': '1.072', 'spread': '65', 'groupId': 'OG001'}, {'value': '2.560', 'spread': '66', 'groupId': 'OG002'}, {'value': '3.134', 'spread': '75', 'groupId': 'OG003'}, {'value': '2.931', 'spread': '624', 'groupId': 'OG004'}, {'value': '14.73', 'spread': '92', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing. Aeτ = Sum of \\[urine concentration \\* sample volume\\] for each collection interval. Aer was summarized by dosing regimen and period.', 'unitOfMeasure': 'mg', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'Percentage of Dose Recovered Unchanged in Urine From Time 0 to the Dosing Interval τ Hours Post-Dose (Aeτ%) (MAD Period Day 10)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.7344', 'spread': '35', 'groupId': 'OG000'}, {'value': '1.072', 'spread': '65', 'groupId': 'OG001'}, {'value': '1.280', 'spread': '66', 'groupId': 'OG002'}, {'value': '0.7827', 'spread': '75', 'groupId': 'OG003'}, {'value': '0.7333', 'spread': '624', 'groupId': 'OG004'}, {'value': '1.228', 'spread': '92', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing. Aeτ% = Aeτ / Dose \\* 100. Aeτ%was summarized by dosing regimen and period.', 'unitOfMeasure': 'Percentage of Dose', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'Renal Clearance (Clr) (MAD Period Day 10)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 30 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 100 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.'}, {'id': 'OG002', 'title': 'PF-06826647 200 mg BID MAD', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.'}, {'id': 'OG003', 'title': 'PF-06826647 400 QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.'}, {'id': 'OG004', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'OG005', 'title': 'PF-06826647 1200 mg QD MAD', 'description': 'In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.2928', 'spread': '70', 'groupId': 'OG000'}, {'value': '0.5500', 'spread': '42', 'groupId': 'OG001'}, {'value': '1.274', 'spread': '39', 'groupId': 'OG002'}, {'value': '0.5777', 'spread': '34', 'groupId': 'OG003'}, {'value': '0.4076', 'spread': '500', 'groupId': 'OG004'}, {'value': '0.9909', 'spread': '58', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Aeτ) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCτ), where dosing interval is 24 hours for QD dosing and 12 hours for BID dosing.', 'unitOfMeasure': 'L/hr', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.'}, {'type': 'SECONDARY', 'title': 'AUCτ (Psoriasis Cohorts)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}, {'id': 'OG001', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '2401', 'spread': '53', 'groupId': 'OG000'}, {'value': '7664', 'spread': '34', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose', 'description': 'AUCτ was summarized by dosing regimen and period. It was determined by linear/log trapezoidal method.', 'unitOfMeasure': 'ng*hr/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.'}, {'type': 'SECONDARY', 'title': 'AUCτ(dn) (Psoriasis Cohorts)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}, {'id': 'OG001', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '24.01', 'spread': '53', 'groupId': 'OG000'}, {'value': '19.17', 'spread': '34', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose', 'description': 'AUCτ(dn) = AUCτ / Dose. To assess the relationship between the PK parameters and the dose, dose normalized AUCτ was plotted against dose, and included individual participant values and the geometric means for each dose.', 'unitOfMeasure': 'ng*hr/mL/mg', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.'}, {'type': 'SECONDARY', 'title': 'Cmax (Psoriasis Cohorts)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}, {'id': 'OG001', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '296.6', 'spread': '38', 'groupId': 'OG000'}, {'value': '869.8', 'spread': '25', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose', 'description': 'Cmax was summarized by dosing regimen and period. It was observed directly from data.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.'}, {'type': 'SECONDARY', 'title': 'Cmax(dn) (Psoriasis Cohorts)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}, {'id': 'OG001', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.966', 'spread': '38', 'groupId': 'OG000'}, {'value': '2.176', 'spread': '25', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose', 'description': 'Cmax was summarized by dosing regimen and period. It was observed directly from data.', 'unitOfMeasure': 'ng/mL/mg', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.'}, {'type': 'SECONDARY', 'title': 'Tmax (Psoriasis Cohorts)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}, {'id': 'OG001', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '4.00', 'groupId': 'OG000', 'lowerLimit': '1.00', 'upperLimit': '6.00'}, {'value': '4.00', 'groupId': 'OG001', 'lowerLimit': '2.00', 'upperLimit': '6.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose', 'description': 'Tmax was summarized by dosing regimen and period. It was observed directly from data as time of first occurrence.', 'unitOfMeasure': 'hours (hr)', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.'}, {'type': 'SECONDARY', 'title': 'Cav (Psoriasis Cohorts)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}, {'id': 'OG001', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '100.2', 'spread': '53', 'groupId': 'OG000'}, {'value': '319.3', 'spread': '34', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose', 'description': "Cav = AUCτ,ss / τ, where ss means 'at steady state'. Cav was summarized by dosing regimen and period.", 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.'}, {'type': 'SECONDARY', 'title': 'Cmin (Psoriasis Cohorts)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}, {'id': 'OG001', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '21.92', 'spread': '103', 'groupId': 'OG000'}, {'value': '38.12', 'spread': '176', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose', 'description': 'Cmin was observed directly from data. It was summarized by dosing regimen and period.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.'}, {'type': 'SECONDARY', 'title': 'Terminal Elimination Half-Life ((t½) (Psoriasis Cohorts)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '11', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}, {'id': 'OG001', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '7.796', 'spread': '5.7087', 'groupId': 'OG000'}, {'value': '6.809', 'spread': '5.4050', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24,168 hours post-dose', 'description': 't1/2 was summarized by dosing regimen and period. It was determined by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.', 'unitOfMeasure': 'hours (hr)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.'}, {'type': 'SECONDARY', 'title': 'MRT (Psoriasis Cohorts)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '11', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}, {'id': 'OG001', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '11.27', 'spread': '41', 'groupId': 'OG000'}, {'value': '9.444', 'spread': '28', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24,168 hours post-dose', 'description': 'MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from time 0 to infinity.', 'unitOfMeasure': 'hours (hr)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.'}, {'type': 'SECONDARY', 'title': 'PTR (Psoriasis Cohorts)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}, {'id': 'OG001', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '13.52', 'spread': '76', 'groupId': 'OG000'}, {'value': '22.81', 'spread': '171', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose', 'description': 'PTR = Cmax,ss / Cmin,ss, it was summarized by dosing regimen and period.', 'unitOfMeasure': 'ratio', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.'}, {'type': 'SECONDARY', 'title': 'Vz/F (Psoriasis Cohorts)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '11', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}, {'id': 'OG001', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '408.1', 'spread': '30', 'groupId': 'OG000'}, {'value': '461.2', 'spread': '54', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose', 'description': 'Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.', 'unitOfMeasure': 'liters (L)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.'}, {'type': 'SECONDARY', 'title': 'CL/F (Psoriasis Cohorts)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}, {'id': 'OG001', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '41.61', 'spread': '53', 'groupId': 'OG000'}, {'value': '52.21', 'spread': '34', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose', 'description': 'CL/F is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.', 'unitOfMeasure': 'L/hr', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'PBO QD PSO', 'description': 'In the psoriasis (PSO) cohorts, psoriasis participants received placebo matching PF-06826647 400, or 100 mg QD PSO cohort for 28 days with standard meal.'}, {'id': 'OG001', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}, {'id': 'OG002', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '-11.13', 'spread': '2.405', 'groupId': 'OG000'}, {'value': '-24.18', 'spread': '2.281', 'groupId': 'OG001'}, {'value': '-14.62', 'spread': '2.505', 'groupId': 'OG002'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline and Day 28', 'description': 'Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0= 0% to 6= 90-100%. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section\\*area score\\*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0= no disease to 72= maximal disease.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The analysis population included psoriasis participants who received the 28-day study treatment and who had the efficacy parameters at Baseline and on Day 28 in the Psoriasis Cohorts. Data in SAD/MAD Periods were not included.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Placebo (PBO) SAD (3 Milligrams [mg], 10 mg)', 'description': 'During the SAD period (Period 1), healthy participants received placebo matching PF-06826647 3, or 10 mg single dose (SD) cohort in fasted state.'}, {'id': 'FG001', 'title': 'PBO SAD Followed by (->) PBO QD MAD', 'description': 'During SAD period (Period 1), healthy participants received placebo matching PF-06826647 30, 100, 400, or 1600 mg SD cohort, respectively, in fasted state. At least 14 days separated the beginning of the SAD and MAD periods. In MAD period (Period 2), these participants received placebo matching PF-06826647 30, 100, 400, or 1600 mg once daily (QD) cohort, respectively, for 10 days with standard meal.'}, {'id': 'FG002', 'title': 'PBO QD MAD Japanese Cohort (JP)', 'description': 'During the MAD period (Period 2), Japanese healthy participants received placebo matching PF-06826647 400 mg QD MAD JP cohort with standard meal. MAD period duration was 28 days.'}, {'id': 'FG003', 'title': 'PBO Twice Daily (BID)', 'description': 'During the MAD period (Period 2), healthy participants received placebo matching PF-06826647 200 mg BID cohort with standard meal.'}, {'id': 'FG004', 'title': 'PF-06826647 3 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state. SAD period duration was 8 days.'}, {'id': 'FG005', 'title': 'PF-06826647 10 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state. SAD period duration was 8 days.'}, {'id': 'FG006', 'title': 'PF-06826647 30 mg SAD -> 30 mg QD MAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state. At least 14 days separated the beginning of the SAD and MAD periods. In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal. SAD period duration was 8 days and MAD period duration was 28 days.'}, {'id': 'FG007', 'title': 'PF-06826647 100 mg SAD -> 100 mg QD MAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state. At least 14 days separated the beginning of the SAD and MAD periods. In the MAD period (Period 2), these healthy participants 4 received PF-06826647 100 mg QD for 10 days with standard meal. SAD period duration was 8 days and MAD period duration was 28 days.'}, {'id': 'FG008', 'title': 'PF-06826647 400 mg SAD -> 400 mg QD MAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state. At least 14 days separated the beginning of the SAD and MAD periods. In the MAD period (Period 2), these healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. SAD period duration was 8 days and MAD period duration was 28 days. SAD period duration was 8 days and MAD period duration was 28 days.'}, {'id': 'FG009', 'title': 'PF-06826647 1600 mg SAD -> 1200 mg QD MAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state. At least 14 days separated the beginning of the SAD and MAD periods. In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal. SAD period duration was 8 days and MAD period duration was 28 days.'}, {'id': 'FG010', 'title': 'PF-06826647 200 mg BID', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'FG011', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'FG012', 'title': 'PBO QD Psoriasis Cohort (PSO)', 'description': 'In the psoriasis placebo cohorts, psoriasis participants received placebo matching PF-06826647 400, or 100 mg QD cohort, respectively, for 28 days with standard meal. Psoriasis cohorts duration was 84 days, safety and AE evaluations lasted up to Day 84, while vital signs, physical, and laboratory abnormality evaluations lasted up to Day 56.'}, {'id': 'FG013', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohorts duration was 84 days, safety and AE evaluations lasted up to Day 84, while vital signs, physical, and laboratory abnormality evaluations lasted up to Day 56.'}, {'id': 'FG014', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohorts duration was 84 days, safety and AE evaluations lasted up to Day 84, while vital signs, physical, and laboratory abnormality evaluations lasted up to Day 56.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '9'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '6'}, {'groupId': 'FG005', 'numSubjects': '6'}, {'groupId': 'FG006', 'numSubjects': '8'}, {'groupId': 'FG007', 'numSubjects': '7'}, {'groupId': 'FG008', 'numSubjects': '8'}, {'groupId': 'FG009', 'numSubjects': '6'}, {'groupId': 'FG010', 'numSubjects': '7'}, {'groupId': 'FG011', 'numSubjects': '5'}, {'groupId': 'FG012', 'numSubjects': '14'}, {'groupId': 'FG013', 'numSubjects': '15'}, {'groupId': 'FG014', 'numSubjects': '11'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '9'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '6'}, {'groupId': 'FG005', 'numSubjects': '6'}, {'groupId': 'FG006', 'numSubjects': '7'}, {'groupId': 'FG007', 'numSubjects': '7'}, {'groupId': 'FG008', 'numSubjects': '8'}, {'groupId': 'FG009', 'numSubjects': '6'}, {'groupId': 'FG010', 'numSubjects': '6'}, {'groupId': 'FG011', 'numSubjects': '5'}, {'groupId': 'FG012', 'numSubjects': '12'}, {'groupId': 'FG013', 'numSubjects': '11'}, {'groupId': 'FG014', 'numSubjects': '9'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '1'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '2'}, {'groupId': 'FG013', 'numSubjects': '4'}, {'groupId': 'FG014', 'numSubjects': '2'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '1'}, {'groupId': 'FG014', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '1'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '1'}]}, {'type': 'No Longer Meets Eligibility Criteria', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '1'}, {'groupId': 'FG014', 'numSubjects': '0'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '1'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '2'}, {'groupId': 'FG013', 'numSubjects': '2'}, {'groupId': 'FG014', 'numSubjects': '0'}]}]}], 'preAssignmentDetails': 'A total of 208 potential participants were screened after signing an informed consent form, of whom 109 participants were randomized to receive study treatment.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '6', 'groupId': 'BG004'}, {'value': '6', 'groupId': 'BG005'}, {'value': '8', 'groupId': 'BG006'}, {'value': '7', 'groupId': 'BG007'}, {'value': '8', 'groupId': 'BG008'}, {'value': '6', 'groupId': 'BG009'}, {'value': '7', 'groupId': 'BG010'}, {'value': '5', 'groupId': 'BG011'}, {'value': '14', 'groupId': 'BG012'}, {'value': '15', 'groupId': 'BG013'}, {'value': '11', 'groupId': 'BG014'}, {'value': '109', 'groupId': 'BG015'}]}], 'groups': [{'id': 'BG000', 'title': 'Placebo (PBO) SAD (3 mg, 10 mg)', 'description': 'During the SAD period (Period 1), healthy participants received placebo matching PF-06826647 3, or 10 mg single dose (SD) cohort in fasted state.'}, {'id': 'BG001', 'title': 'PBO SAD Followed by (->) PBO QD MAD', 'description': 'During SAD period (Period 1), healthy participants received placebo matching PF-06826647 30, 100, 400, or 1600 mg SD cohort, respectively, in fasted state. At least 14 days separated the beginning of the SAD and MAD periods. In MAD period (Period 2), these participants received placebo matching PF-06826647 30, 100, 400, or 1600 mg once daily (QD) cohort, respectively, for 10 days with standard meal.'}, {'id': 'BG002', 'title': 'PBO QD MAD Japanese Cohort (JP)', 'description': 'During the MAD period (Period 2), Japanese healthy participants received placebo matching PF-06826647 400 mg QD MAD JP cohort with standard meal. MAD period duration was 28 days.'}, {'id': 'BG003', 'title': 'PBO BID', 'description': 'During the MAD period (Period 2), healthy participants received placebo matching PF-06826647 200 mg BID cohort with standard meal.'}, {'id': 'BG004', 'title': 'PF-06826647 3 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state. SAD period duration was 8 days.'}, {'id': 'BG005', 'title': 'PF-06826647 10 mg SAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state. SAD period duration was 8 days.'}, {'id': 'BG006', 'title': 'PF-06826647 30 mg SAD -> 30 mg QD MAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state. At least 14 days separated the beginning of the SAD and MAD periods. In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal. SAD period duration was 8 days and MAD period duration was 28 days.'}, {'id': 'BG007', 'title': 'PF-06826647 100 mg SAD -> 100 mg QD MAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state. At least 14 days separated the beginning of the SAD and MAD periods. In the MAD period (Period 2), these healthy participants 4 received PF-06826647 100 mg QD for 10 days with standard meal. SAD period duration was 8 days and MAD period duration was 28 days.'}, {'id': 'BG008', 'title': 'PF-06826647 400 mg SAD -> 400 mg QD MAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state. At least 14 days separated the beginning of the SAD and MAD periods. In the MAD period (Period 2), these healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. SAD period duration was 8 days and MAD period duration was 28 days. SAD period duration was 8 days and MAD period duration was 28 days.'}, {'id': 'BG009', 'title': 'PF-06826647 1600 mg SAD -> 1200 mg QD MAD', 'description': 'During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state. At least 14 days separated the beginning of the SAD and MAD periods. In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal. SAD period duration was 8 days and MAD period duration was 28 days.'}, {'id': 'BG010', 'title': 'PF-06826647 200 mg BID', 'description': 'During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'BG011', 'title': 'PF-06826647 400 mg QD MAD JP', 'description': 'During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.'}, {'id': 'BG012', 'title': 'PBO QD Psoriasis Cohort (PSO)', 'description': 'In the psoriasis placebo cohorts, psoriasis participants received placebo matching PF-06826647 400, or 100 mg QD cohort, respectively, for 28 days with standard meal. Psoriasis cohorts duration was 84 days, safety and AE evaluations lasted up to Day 84, while vital signs, physical, and laboratory abnormality evaluations lasted up to Day 56.'}, {'id': 'BG013', 'title': 'PF-06826647 400 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohorts duration was 84 days, safety and AE evaluations lasted up to Day 84, while vital signs, physical, and laboratory abnormality evaluations lasted up to Day 56.'}, {'id': 'BG014', 'title': 'PF-06826647 100 mg QD PSO', 'description': 'In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohorts duration was 84 days, safety and AE evaluations lasted up to Day 84, while vital signs, physical, and laboratory abnormality evaluations lasted up to Day 56.'}, {'id': 'BG015', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '38.5', 'spread': '12.23', 'groupId': 'BG000'}, {'value': '42.2', 'spread': '10.84', 'groupId': 'BG001'}, {'value': '34.0', 'spread': 'NA', 'comment': 'only 1 participant in this cohort', 'groupId': 'BG002'}, {'value': '32.5', 'spread': '4.95', 'groupId': 'BG003'}, {'value': '44.3', 'spread': '11.47', 'groupId': 'BG004'}, {'value': '40.2', 'spread': '10.30', 'groupId': 'BG005'}, {'value': '40.5', 'spread': '11.64', 'groupId': 'BG006'}, {'value': '36.9', 'spread': '7.40', 'groupId': 'BG007'}, {'value': '37.5', 'spread': '8.23', 'groupId': 'BG008'}, {'value': '31.2', 'spread': '5.00', 'groupId': 'BG009'}, {'value': '37.4', 'spread': '9.27', 'groupId': 'BG010'}, {'value': '39.8', 'spread': '5.40', 'groupId': 'BG011'}, {'value': '38.3', 'spread': '13.25', 'groupId': 'BG012'}, {'value': '40.9', 'spread': '11.62', 'groupId': 'BG013'}, {'value': '39.0', 'spread': '13.39', 'groupId': 'BG014'}, {'value': '39.0', 'spread': '10.53', 'groupId': 'BG015'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '1', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '0', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '3', 'groupId': 'BG015'}]}, {'title': 'Male', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '6', 'groupId': 'BG004'}, {'value': '5', 'groupId': 'BG005'}, {'value': '8', 'groupId': 'BG006'}, {'value': '7', 'groupId': 'BG007'}, {'value': '7', 'groupId': 'BG008'}, {'value': '6', 'groupId': 'BG009'}, {'value': '7', 'groupId': 'BG010'}, {'value': '5', 'groupId': 'BG011'}, {'value': '14', 'groupId': 'BG012'}, {'value': '15', 'groupId': 'BG013'}, {'value': '11', 'groupId': 'BG014'}, {'value': '106', 'groupId': 'BG015'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '3', 'groupId': 'BG006'}, {'value': '1', 'groupId': 'BG007'}, {'value': '4', 'groupId': 'BG008'}, {'value': '4', 'groupId': 'BG009'}, {'value': '2', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '7', 'groupId': 'BG012'}, {'value': '4', 'groupId': 'BG013'}, {'value': '8', 'groupId': 'BG014'}, {'value': '40', 'groupId': 'BG015'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '6', 'groupId': 'BG004'}, {'value': '6', 'groupId': 'BG005'}, {'value': '5', 'groupId': 'BG006'}, {'value': '6', 'groupId': 'BG007'}, {'value': '4', 'groupId': 'BG008'}, {'value': '2', 'groupId': 'BG009'}, {'value': '5', 'groupId': 'BG010'}, {'value': '5', 'groupId': 'BG011'}, {'value': '7', 'groupId': 'BG012'}, {'value': '11', 'groupId': 'BG013'}, {'value': '3', 'groupId': 'BG014'}, {'value': '69', 'groupId': 'BG015'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '0', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '0', 'groupId': 'BG015'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '0', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '0', 'groupId': 'BG015'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '1', 'groupId': 'BG006'}, {'value': '2', 'groupId': 'BG007'}, {'value': '1', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '5', 'groupId': 'BG011'}, {'value': '1', 'groupId': 'BG012'}, {'value': '3', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '17', 'groupId': 'BG015'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '1', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '1', 'groupId': 'BG015'}]}, {'title': 'Black or African American', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}, {'value': '4', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '1', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '3', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '2', 'groupId': 'BG012'}, {'value': '1', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '17', 'groupId': 'BG015'}]}, {'title': 'White', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '6', 'groupId': 'BG006'}, {'value': '3', 'groupId': 'BG007'}, {'value': '6', 'groupId': 'BG008'}, {'value': '5', 'groupId': 'BG009'}, {'value': '4', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '11', 'groupId': 'BG012'}, {'value': '9', 'groupId': 'BG013'}, {'value': '11', 'groupId': 'BG014'}, {'value': '69', 'groupId': 'BG015'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '1', 'groupId': 'BG006'}, {'value': '1', 'groupId': 'BG007'}, {'value': '1', 'groupId': 'BG008'}, {'value': '1', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '1', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '5', 'groupId': 'BG015'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '0', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '0', 'groupId': 'BG015'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'All enrolled participants who received at least 1 dose of study medication.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2018-04-05', 'size': 2751929, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2020-01-13T12:41', 'hasProtocol': True}, {'date': '2018-06-12', 'size': 1479127, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2020-01-13T12:41', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR'], 'maskingDescription': 'Double blind treatment'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL', 'interventionModelDescription': 'Combination single and multiple ascending dose design. Cohorts of participants are assigned to receive interventions based on acceptable safety, tolerability, and pharmacokinetics of previous dose cohort'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 109}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2017-07-14', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-03', 'completionDateStruct': {'date': '2019-01-25', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-03-28', 'studyFirstSubmitDate': '2017-07-03', 'resultsFirstSubmitDate': '2020-01-13', 'studyFirstSubmitQcDate': '2017-07-05', 'lastUpdatePostDateStruct': {'date': '2020-03-31', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2020-03-28', 'studyFirstPostDateStruct': {'date': '2017-07-07', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2020-03-31', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-01-25', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Participants With Vital Signs Data Meeting Pre-Specified Criteria (Single Ascending Dose [SAD] Period)', 'timeFrame': 'Baseline up to Day 8', 'description': 'Maximum absolute values and changes from baseline for vital signs (for supine systolic/diastolic blood pressure \\[BP\\] and supine pulse rate \\[PR\\]) were summarized descriptively by treatment. Numbers of participants meeting the categorical criteria were provided.\n\nNumber of participants in PBO SAD cohorts = number of participants in \\[PBO SAD (3mg, 10mg)\\] cohorts + number of participants in \\[PBO SAD -\\> PBO QD MAD\\] cohorts.'}, {'measure': 'Number of Participants With Vital Signs Data Meeting Pre-Specified Criteria (Multiple Ascending Dose [MAD] Period)', 'timeFrame': 'Baseline up to Day 28', 'description': 'Maximum absolute values and changes from baseline for vital signs (for supine systolic/diastolic blood pressure and supine pulse rate) were summarized descriptively by treatment. Numbers of participants meeting the categorical criteria were provided.'}, {'measure': 'Number of Participants With Vital Signs Data Meeting Pre-Specified Criteria (Psoriasis Cohorts)', 'timeFrame': 'Baseline up to Day 56', 'description': 'Maximum absolute values and changes from baseline for vital signs (for supine systolic/diastolic blood pressure and supine pulse rate) were summarized descriptively by treatment. Numbers of participants meeting the categorical criteria were provided.'}, {'measure': 'Number of Participants With Physical Examination Data Meeting Pre-Specified Criteria (SAD Period)', 'timeFrame': 'Baseline up to Day 8', 'description': "Physical examinations were conducted by a physician, trained physician assistant, or nurse practitioner as acceptable according to local regulation. A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Findings were considered to be clinically significant based on investigator's decision.\n\nNumber of participants in PBO SAD cohorts = number of participants in \\[PBO SAD (3mg, 10mg)\\] cohorts + number of participants in \\[PBO SAD -\\> PBO QD MAD\\] cohorts."}, {'measure': 'Number of Participants With Physical Examination Data Meeting Pre-Specified Criteria (MAD Period)', 'timeFrame': 'Baseline up to Day 28', 'description': "Physical examinations were conducted by a physician, trained physician assistant, or nurse practitioner as acceptable according to local regulation. A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Findings were considered to be clinically significant based on investigator's decision."}, {'measure': 'Number of Participants With Physical Examination Data Meeting Pre-Specified Criteria (Psoriasis Cohorts)', 'timeFrame': 'Baseline up to Day 56', 'description': "Physical examinations were conducted by a physician, trained physician assistant, or nurse practitioner as acceptable according to local regulation. A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Findings were considered to be clinically significant based on investigator's decision."}, {'measure': 'Number of Participants With Electrocardiogram (ECG) Data Meeting Pre-Specified Criteria (SAD Period)', 'timeFrame': 'Baseline up to Day 8', 'description': 'ECG endpoints and changes from baseline (QTcF, PR and QRS) were summarized descriptively by cohort and treatment using pre-defined categories. Numbers of participants meeting the categorical criteria were provided. All planned and unplanned post-dose time points were counted in these categorical summaries. Categorical summarization criteria for ECG were as follows: 1) QTcF maximum absolute value ≥450 and \\<480 millisecond (msec), ≥480 and \\<500 msec. ≥500 msec; 2) QTcF maximum increase ≥30 and \\<60 msec, ≥60 msec; 3) PR maximum absolute value ≥300 msec; 4) PR maximum increases from baseline ≥25% if baseline \\>200 msec, ≥50% if baseline ≤200 msec; 5) QRS maximum absolute value ≥140 msec; 6) QRS maximum increase from baseline ≥50%.\n\nNumber of participants in PBO SAD cohorts = number of participants in \\[PBO SAD (3mg, 10mg)\\] cohorts + number of participants in \\[PBO SAD -\\> PBO QD MAD\\] cohorts.'}, {'measure': 'Number of Participants With ECG Data Meeting Pre-Specified Criteria (MAD Period)', 'timeFrame': 'Baseline up to Day 28', 'description': 'ECG endpoints and changes from baseline (QTcF, PR and QRS) were summarized descriptively by cohort and treatment using pre-defined categories. Numbers of participants meeting the categorical criteria were provided. All planned and unplanned post-dose time points were counted in these categorical summaries. Categorical summarization criteria for ECG were as follows: 1) QTcF maximum absolute value ≥450 and \\<480 millisecond (msec), ≥480 and \\<500 msec. ≥500 msec; 2) QTcF maximum increase ≥30 and \\<60 msec, ≥60 msec; 3) PR maximum absolute value ≥300 msec; 4) PR maximum increases from baseline ≥25% if baseline \\>200 msec, ≥50% if baseline ≤200 msec; 5) QRS maximum absolute value ≥140 msec; 6) QRS maximum increase from baseline ≥50%.'}, {'measure': 'Number of Participants With ECG Data Meeting Pre-Specified Criteria (Psoriasis Cohorts)', 'timeFrame': 'Baseline up to Day 56', 'description': 'ECG endpoints and changes from baseline (QTcF, PR and QRS) were summarized descriptively by cohort and treatment using pre-defined categories. Numbers of participants meeting the categorical criteria were provided. All planned and unplanned post-dose time points were counted in these categorical summaries. Categorical summarization criteria for ECG were as follows: 1) QTcF maximum absolute value ≥450 and \\<480 millisecond (msec), ≥480 and \\<500 msec. ≥500 msec; 2) QTcF maximum increase ≥30 and \\<60 msec, ≥60 msec; 3) PR maximum absolute value ≥300 msec; 4) PR maximum increases from baseline ≥25% if baseline \\>200 msec, ≥50% if baseline ≤200 msec; 5) QRS maximum absolute value ≥140 msec; 6) QRS maximum increase from baseline ≥50%.'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Who Withdrew Due to Adverse Events (AEs) (SAD Period)', 'timeFrame': 'Baseline up to Day 8', 'description': 'An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. All events occurring following start of the treatment or increasing in severity were counted as treatment emergent. Events that occurred in a non-treatment period (eg, washout or follow-up) were counted as treatment emergent and attributed to the previous treatment taken. For each event, the investigator pursued and obtained adequate information both to determine the outcome and to assess whether it meets the criteria for classification as an SAE.\n\nPBO SAD cohorts = \\[PBO SAD (3mg, 10mg)\\] cohorts + \\[PBO SAD -\\> PBO QD MAD\\] cohorts.'}, {'measure': 'Number of Participants With TEAEs, SAEs, and Who Withdrew Due to AEs (MAD Period)', 'timeFrame': 'Baseline up to Day 28', 'description': 'An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. All events occurring following start of the treatment or increasing in severity were counted as treatment emergent. Events that occurred in a non-treatment period (eg, washout or follow-up) were counted as treatment emergent and attributed to the previous treatment taken. For each event, the investigator pursued and obtained adequate information both to determine the outcome and to assess whether it meets the criteria for classification as an SAE.'}, {'measure': 'Number of Participants With TEAEs, SAEs, and Who Withdrew Due to AEs (Psoriasis Cohorts)', 'timeFrame': 'Baseline up to Day 84', 'description': 'An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. All events occurring following start of the treatment or increasing in severity were counted as treatment emergent. Events that occurred in a non-treatment period (eg, washout or follow-up) were counted as treatment emergent and attributed to the previous treatment taken. For each event, the investigator pursued and obtained adequate information both to determine the outcome and to assess whether it meets the criteria for classification as an SAE.'}, {'measure': 'Number of Participants With Laboratory Abnormalities (SAD Period)', 'timeFrame': 'Baseline up to Day 8', 'description': 'Laboratory data were listed and summarized by treatment in accordance with the sponsor reporting standards. Parameters for laboratory abnormalities evaluation included: erythrocyte mean corpuscular volume (Ery. MCV), erythrocyte mean corpuscular hemoglobin (Ery. MCH), reticulocytes/erythrocytes (%), limphocytes, eosinophils, bilirubin, aspartate aminotransferase (AST), urate, high-density lipoproteins (HDL) cholesterol, low-density lipoproteins (LDL) cholesterol, triglycerides, cholesterol, ketones, nitrite, leukocyte esterase, epithelial cells, urinalysis-bacteria.\n\nNumber of participants in PBO SAD cohorts = number of participants in \\[PBO SAD (3mg, 10mg)\\] cohorts + number of participants in \\[PBO SAD -\\> PBO QD MAD\\] cohorts.'}, {'measure': 'Number of Participants With Laboratory Abnormalities (MAD Period)', 'timeFrame': 'Baseline up to Day 28', 'description': 'Laboratory data were listed and summarized by treatment in accordance with the sponsor reporting standards. Parameters and corresponding primary criteria for laboratory abnormalities evaluation included: Ery. MCV \\<0.9 × LLN, Ery. Mean corpuscular hemoglobin (Ery. MCH) \\<0.9 × LLN or \\>1.1 ULN, reticulocytes/erythrocytes (%) \\>1.5 × ULN, lymphocytes \\<0.8 × LLN or \\>1.2 × ULN, neutrophils \\<0.8 × LLN, eosinophils \\>1.2 × ULN, bilirubin \\>1.5 × ULN, urate \\>1.2 × ULN, HDL cholesterol \\<0.8 × LLN, LDL cholesterol \\>1.2 × ULN, triglycerides \\>1.3 × ULN, bicarbonate \\>1.1 × ULN, cholesterol \\>1.3 × ULN, urine glucose ≥1, urine hemoglobin ≥1, nitrite ≥1, leukocyte esterase ≥1, epithelial cells ≥6/LPF, urinalysis-casts \\>1/LPF, urinalysis-bacteria \\>20/HPF, urine 24 hours creatinine \\>1.1 × ULN.'}, {'measure': 'Number of Participants With Laboratory Abnormalities (Psoriasis Cohorts)', 'timeFrame': 'Baseline up to Day 56', 'description': 'Laboratory data were listed and summarized by treatment in accordance with the sponsor reporting standards. Parameters and corresponding primary criteria for laboratory abnormalities evaluation included: reticulocytes/erythrocytes (%) \\>1.5 × ULN, lymphocytes \\<0.8 × LLN, neutrophils \\<0.8 × LLN or \\>1.2 × ULN, eosinophils \\>1.2 × ULN, bilirubin \\>1.5 × ULN, alanine aminotransferase (ALT) \\>3.0 × ULN, creatinine \\>1.3 × ULN, urate \\>1.2 × ULN, HDL cholesterol \\<0.8 × LLN, LDL cholesterol \\>1.2 × ULN, triglycerides \\>1.3 × ULN, potassium \\>1.1 × ULN, bicarbonate \\>1.1 × ULN, glucose \\<0.6 × LLN or \\>1.5 × ULN, Creatine Kinase (CK) \\>2.0 × ULN, cholesterol \\>1.3 × ULN, urine glucose ≥1, ketones ≥1, urine hemoglobin ≥1, urine bilirubin ≥1, leukocyte esterase ≥1, epithelial cells ≥6/LPF, urinalysis-bacteria/HPF.'}, {'measure': 'Change in 24 Hour Creatinine Clearance From Day -1 on Day 10 (MAD Period)', 'timeFrame': 'Day -1 and Day 10', 'description': 'Change in 24-hour creatinine clearance at Day 10 from Day -1 (baseline) during the MAD was presented by treatment group.'}], 'secondaryOutcomes': [{'measure': 'Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) (SAD Period)', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 'AUCinf = Area under the plasma concentration versus time curve (AUC) from time 0 (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).'}, {'measure': 'Secondary: Dose Normalized AUCinf (AUCinf[dn]) (SAD Period)', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 'AUCinf = Area under the plasma concentration versus time curve (AUC) from time 0 (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf). AUCinf(dn) = AUCinf / dose. Dose normalized AUC values of PF-06826647 was plotted against dose and included individual participant values and the geometric means for each dose. These plots were used to help understand the relationship between the plasma PK parameters and dose.'}, {'measure': 'Area Under the Concentration-Time Profile From Time 0 to 24 Hours (AUC24) (SAD Period)', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'AUC24 was summarized by dosing regimen and period. It was determined by linear/log trapezoidal method.'}, {'measure': 'Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) (SAD Period)', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 'AUClast was summarized by dosing regimen and period. It was determined by linear/log trapezoidal method.'}, {'measure': 'Dose Normalized AUClast (AUClast[dn]) (SAD Period)', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 'AUClast(dn) = AUClast / dose. Dose normalized AUC values of PF-06826647 were plotted against dose and included individual participant values and the geometric means for each dose. These plots was used to help understand the relationship between the plasma PK parameters and dose.'}, {'measure': 'Maximum Plasma Concentration (Cmax) (SAD Period)', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 'Cmax was summarized by dosing regimen and period. It was observed directly from data.'}, {'measure': 'Dose Normalized Cmax (Cmax[dn]) (SAD Period)', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 'Cmax(dn) = Cmax / dose. To assess the relationship between Cmax and dose, dose normalized Cmax was plotted against dose, and included individual participant values and the geometric means for each dose.'}, {'measure': 'Time for Cmax (Tmax) (SAD Period)', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 'Tmax was summarized by dosing regimen and period. It was observed directly from data as time of first occurrence.'}, {'measure': 'Terminal Elimination Half-Life ((t½) (SAD Period)', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 't1/2 was summarized by dosing regimen and period. It was determined by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.'}, {'measure': 'Mean Residence Time (MRT) (SAD Period)', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 'MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from time 0 to infinity.'}, {'measure': 'Apparent Volume of Distribution (Vz/F) (SAD Period)', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 'Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.'}, {'measure': 'Apparent Clearance (CL/F) (SAD Period)', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose', 'description': 'CL/F is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.'}, {'measure': 'Area Under the Plasma Concentration-Time Profile Over the Dosing Interval τ (AUCτ) (MAD Period Day 1)', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'AUCτ was summarized by dosing regimen and period. Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval was 24 hours for QD dosing and 12 hours for BID dosing. It was determined by linear/log trapezoidal method.'}, {'measure': 'Dose Normalized AUCτ (AUCτ[dn]) (MAD Period Day 1)', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Area Under the Plasma Concentration-Time Profile over the Dosing interval τ (AUCτ). Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing.\n\nAUCτ(dn) = AUCτ / Dose. To assess the relationship between the PK parameters and the dose, dose normalized AUCτ was plotted against dose, and included individual participant values and the geometric means for each dose.'}, {'measure': 'Cmax (MAD Period Day 1)', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Cmax was summarized by dosing regimen and period. It was observed directly from data.'}, {'measure': 'Cmax(dn) (MAD Period Day 1)', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Cmax(dn) = Cmax / dose. To assess the relationship between Cmax and dose, dose normalized Cmax was plotted against dose, and included individual participant values and the geometric means for each dose.'}, {'measure': 'Tmax (MAD Period Day 1)', 'timeFrame': 'Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Tmax was summarized by dosing regimen and period. It was observed directly from data as time of first occurrence.'}, {'measure': 'AUCτ (MAD Period Day 10)', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'AUCτ was summarized by dosing regimen and period. Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval was 24 hours for QD dosing and 12 hours for BID dosing. It was determined by linear/log trapezoidal method.'}, {'measure': 'AUCτ(dn) (MAD Period Day 10)', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Area Under the Plasma Concentration-Time Profile over the Dosing interval τ (AUCτ). Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing.\n\nAUCτ(dn) = AUCτ / Dose. To assess the relationship between the PK parameters and the dose, dose normalized AUCτ was plotted against dose, and included individual participant values and the geometric means for each dose.'}, {'measure': 'Cmax (MAD Period Day 10)', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Cmax was summarized by dosing regimen and period. It was observed directly from data.'}, {'measure': 'Cmax(dn) (MAD Period Day 10)', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Cmax(dn) = Cmax / dose. To assess the relationship between Cmax and dose, dose normalized Cmax was plotted against dose, and included individual participant values and the geometric means for each dose.'}, {'measure': 'Tmax (MAD Period Day 10)', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Tmax was summarized by dosing regimen and period. It was observed directly from data as time of first occurrence.'}, {'measure': 'Average Concentration at Steady State (Cav) (MAD Period Day 10)', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': "Cav = AUCτ,ss / τ, where ss means 'at steady state', and where the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing. Cav was summarized by dosing regimen and period."}, {'measure': 'Lowest Concentration Observed During the Dosing Interval τ (Cmin) (MAD Period Day 10)', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Cmin was observed directly from data. It was summarized by dosing regimen and period. Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing.'}, {'measure': 'Terminal Elimination Half-Life ((t½) (MAD Period Day 10)', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24,48,72,96,168 hours post-dose', 'description': 't1/2 was summarized by dosing regimen and period. It was determined by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.'}, {'measure': 'MRT (MAD Period Day 10)', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24,48,72,96,168 hours post-dose', 'description': 'MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from time 0 to infinity.'}, {'measure': 'Peak Trough Ratio (PTR) (MAD Period Day 10)', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': "PTR = Cmax,ss / Cmin,ss, where ss means 'at steady state'. It was summarized by dosing regimen and period."}, {'measure': 'Observed Accumulation Ratio Based on AUC (Rac) (MAD Period Day 10)', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': "Rac = AUCτ,ss / AUCτ,sd, where ss means 'at steady state' and sd 'single dose'. In this study, Rac = AUCτ(Day 10) / AUCτ(Day 1). Rac was summarized by dosing regimen and period."}, {'measure': 'Observed Accumulation Ratio Based on Cmax (Rac,Cmax) (MAD Period Day 10)', 'timeFrame': 'Days 1 and 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': "Rac,Cmax = Cmax,ss / Cmax,sd, where ss means 'at steady state' and sd 'single dose'. In this study, Rac,Cmax = Cmax(Day10) / Cmax(Day 1). Rac,Cmax was summarized by dosing regimen and period."}, {'measure': 'Vz/F (MAD Period Day 10)', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.'}, {'measure': 'CL/F (MAD Period Day 10)', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'CL/F is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.'}, {'measure': 'Cumulative Amount of Drug Recovered Unchanged in Urine From Time 0 to the Dosing Interval τ Hours Post-Dose (Aeτ) (MAD Period Day 10)', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing. Aeτ = Sum of \\[urine concentration \\* sample volume\\] for each collection interval. Aer was summarized by dosing regimen and period.'}, {'measure': 'Percentage of Dose Recovered Unchanged in Urine From Time 0 to the Dosing Interval τ Hours Post-Dose (Aeτ%) (MAD Period Day 10)', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing. Aeτ% = Aeτ / Dose \\* 100. Aeτ%was summarized by dosing regimen and period.'}, {'measure': 'Renal Clearance (Clr) (MAD Period Day 10)', 'timeFrame': 'Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose', 'description': 'Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Aeτ) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCτ), where dosing interval is 24 hours for QD dosing and 12 hours for BID dosing.'}, {'measure': 'AUCτ (Psoriasis Cohorts)', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose', 'description': 'AUCτ was summarized by dosing regimen and period. It was determined by linear/log trapezoidal method.'}, {'measure': 'AUCτ(dn) (Psoriasis Cohorts)', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose', 'description': 'AUCτ(dn) = AUCτ / Dose. To assess the relationship between the PK parameters and the dose, dose normalized AUCτ was plotted against dose, and included individual participant values and the geometric means for each dose.'}, {'measure': 'Cmax (Psoriasis Cohorts)', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose', 'description': 'Cmax was summarized by dosing regimen and period. It was observed directly from data.'}, {'measure': 'Cmax(dn) (Psoriasis Cohorts)', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose', 'description': 'Cmax was summarized by dosing regimen and period. It was observed directly from data.'}, {'measure': 'Tmax (Psoriasis Cohorts)', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose', 'description': 'Tmax was summarized by dosing regimen and period. It was observed directly from data as time of first occurrence.'}, {'measure': 'Cav (Psoriasis Cohorts)', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose', 'description': "Cav = AUCτ,ss / τ, where ss means 'at steady state'. Cav was summarized by dosing regimen and period."}, {'measure': 'Cmin (Psoriasis Cohorts)', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose', 'description': 'Cmin was observed directly from data. It was summarized by dosing regimen and period.'}, {'measure': 'Terminal Elimination Half-Life ((t½) (Psoriasis Cohorts)', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24,168 hours post-dose', 'description': 't1/2 was summarized by dosing regimen and period. It was determined by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.'}, {'measure': 'MRT (Psoriasis Cohorts)', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24,168 hours post-dose', 'description': 'MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from time 0 to infinity.'}, {'measure': 'PTR (Psoriasis Cohorts)', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose', 'description': 'PTR = Cmax,ss / Cmin,ss, it was summarized by dosing regimen and period.'}, {'measure': 'Vz/F (Psoriasis Cohorts)', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose', 'description': 'Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.'}, {'measure': 'CL/F (Psoriasis Cohorts)', 'timeFrame': 'Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose', 'description': 'CL/F is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.'}, {'measure': 'Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 28', 'timeFrame': 'Baseline and Day 28', 'description': 'Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0= 0% to 6= 90-100%. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section\\*area score\\*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0= no disease to 72= maximal disease.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Plaque Psoriasis']}, 'referencesModule': {'references': [{'pmid': '38279383', 'type': 'DERIVED', 'citation': 'Tehlirian C, Peeva E, Kieras E, Scaramozza M, Roberts ES, Singh RSP, Pradhan V, Banerjee A, Garcet S, Xi L, Gale JD, Vincent MS, Krueger J. Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study. Lancet Rheumatol. 2021 Mar;3(3):e204-e213. doi: 10.1016/S2665-9913(20)30397-0. Epub 2020 Dec 24.'}], 'seeAlsoLinks': [{'url': 'https://pmiform.com/clinical-trial-info-request?StudyID=C2501001', 'label': 'To obtain contact information for a study center near you, click here.'}]}, 'descriptionModule': {'briefSummary': 'This first in human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-06826647 in healthy subjects and subjects with plaque psoriasis.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '55 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Healthy Participants:\n\nInclusion Criteria:\n\n* Healthy male subjects between ages of 18-55 years\n* Healthy female subjects of non-childbearing potential between the ages of 18-55 years\n* Body Mass Index (BMI) of 17.5 to 30.5kg/m2; and a total body weight \\>50kg (110lbs).\n* No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)\n* (Optional) Japanese subjects who have four Japanese biologic grandparents born in Japan\n\nExclusion Criteria:\n\n* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)\n* Pregnant female subjects; breastfeeding female subjects; female subjects of childbearing potential\n* Fertile male subjects who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product\n* Have a clinically significant infection currently or within 6 months of first dose of study drug\n\nPsoriasis Participants:\n\nInclusion Criteria:\n\n* Healthy male subjects between ages of 18-65 years\n* Healthy female subjects of non-childbearing potential between the ages of 18-65 years\n* Have a diagnosis of plaque psoriasis for at least 6 months prior to first study dose\n* Have plaque-type psoriasis covering at least 15% of total body surface area (BSA) at Day-1(prior to randomization in the study\n* No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)\n\nExclusion Criteria:\n\n* Currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular psoriasis\n* Have a clinically significant infection currently or within 6 months of first dose of study drug, or a history of chronic or recurrent infectious disease\n* Pregnant female subjects; breastfeeding female subjects; female subjects of childbearing potential\n* Fertile male subjects who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product'}, 'identificationModule': {'nctId': 'NCT03210961', 'briefTitle': 'A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis', 'organization': {'class': 'INDUSTRY', 'fullName': 'Pfizer'}, 'officialTitle': 'A PHASE 1, WITHIN COHORT, RANDOMIZED, DOUBLE BLIND, THIRD-PARTY OPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE DOSE ESCALATION, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-06826647 IN HEALTHY SUBJECTS AND SUBJECTS WITH PLAQUE PSORIASIS', 'orgStudyIdInfo': {'id': 'C2501001'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'PF-06826647 tablet', 'interventionNames': ['Drug: PF-06826647 tablet']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo tablet', 'interventionNames': ['Other: Placebo tablet']}, {'type': 'EXPERIMENTAL', 'label': 'PF-06826647 oral suspension', 'interventionNames': ['Drug: PF-06826647 oral suspension']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo oral solution/suspension', 'interventionNames': ['Other: Placebo oral solution/suspension']}], 'interventions': [{'name': 'PF-06826647 tablet', 'type': 'DRUG', 'description': 'PF-06826647 tablet for oral administration', 'armGroupLabels': ['PF-06826647 tablet']}, {'name': 'PF-06826647 oral suspension', 'type': 'DRUG', 'description': 'PF-06826647 suspension for oral administration (oral suspension to be administered to the 3mg starting dose cohort only)', 'armGroupLabels': ['PF-06826647 oral suspension']}, {'name': 'Placebo oral solution/suspension', 'type': 'OTHER', 'description': 'placebo oral solution for the single ascending dose, first cohort only', 'armGroupLabels': ['Placebo oral solution/suspension']}, {'name': 'Placebo tablet', 'type': 'OTHER', 'description': 'Matching placebo tablet', 'armGroupLabels': ['Placebo tablet']}]}, 'contactsLocationsModule': {'locations': [{'zip': '92801', 'city': 'Anaheim', 'state': 'California', 'country': 'United States', 'facility': 'Anaheim Clinical Trials, LLC', 'geoPoint': {'lat': 33.83529, 'lon': -117.9145}}], 'overallOfficials': [{'name': 'Pfizer CT.gov Call Center', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Pfizer'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': "Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\\_trials/trial\\_data\\_and\\_results/data\\_requests."}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Pfizer', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}